Allarity Therapeutics (ALLR) 10-Q 14 Nov 24 2024 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2024	Nov. 13, 2024	May 02, 2024
Document Information [Line Items]
Entity Central Index Key	0001860657
Entity Registrant Name	Allarity Therapeutics, Inc.
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2024
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2024
Document Transition Report	false
Entity File Number	001-41160
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	87-2147982
Entity Address, Address Line One	24 School Street, 2nd Floor
Entity Address, City or Town	Boston
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02108
City Area Code	401
Local Phone Number	426-4664
Title of 12(b) Security	Common Stock, $0.0001 par value per share
Trading Symbol	ALLR
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		4,433,587
Minimum [Member]
Document Information [Line Items]
Entity Public Float			$ 75

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Current assets
Cash and cash equivalents	$ 18,463	$ 166
Other current assets	100	209
Prepaid expenses	151	781
Tax credit receivable	1,652	815
Total current assets	20,366	1,971
Property, plant and equipment, net	12	20
Intangible assets	0	9,871
Total assets	20,378	11,862
Current liabilities
Accounts Payable, Current	4,693	8,416
Accrued Liabilities, Current	1,322	1,309
Warrant derivative liability	2	3,083
Income taxes payable	60	59
Convertible promissory notes and accrued interest, net of debt discount	1,337	1,300
Total current liabilities	7,414	14,167
Deferred tax	0	446
Total liabilities	7,414	14,613
Commitments and contingencies (Note 14)
Stockholders’ equity (deficit)
Series A Preferred stock $0.0001 par value (500,000 and 20,000 shares designated at September 30, 2024 and December 31, 2023, respectively) shares issued and outstanding at September 30, 2024 and December 31, 2023 were 0 and 1,417, respectively	0	1,742
Common stock, $0.0001 par value (250,000,000 and 750,000,000 shares authorized, at September 30, 2024 and December 31, 2023, respectively); shares issued and outstanding at September 30, 2024 and December 31, 2023 were 2,759,070 and 9,812, respectively	0	0
Additional paid-in capital	125,170	90,369
Accumulated other comprehensive loss	(693)	(411)
Accumulated deficit	(111,513)	(94,451)
Total stockholders’ equity (deficit)	12,964	(2,751)
Total liabilities and stockholders’ equity (deficit)	$ 20,378	$ 11,862

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Sep. 30, 2024	Dec. 31, 2023
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, designated (in shares)	500,000	20,000
Preferred stock, issued (in shares)	0	1,417
Preferred stock, outstanding (in shares)	0	1,417
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, authorized (in shares)	250,000,000	750,000,000
Common stock, issued (in shares)	2,759,070	9,812
Common stock, outstanding (in shares)	2,759,070	9,812

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Operating expenses
Research and development	$ 1,021	$ 1,948	$ 4,249	$ 4,480
Impairment of intangible assets	9,703	0	9,703	0
General and administrative	1,589	2,478	5,972	7,770
Total operating expenses	12,313	4,426	19,924	12,250
Loss from operations	(12,313)	(4,426)	(19,924)	(12,250)
Other income (expense)
Interest income	261	12	314	19
Interest expense	(50)	(34)	(578)	(268)
Foreign exchange (losses) gains	121	(156)	69	(87)
Change in fair value of derivative and warrant liabilities	14	4,937	2,676	7,187
Total other income (expense)	346	(21)	2,481	2,071
Net loss before tax benefit	(11,967)	(4,447)	(17,443)	(10,179)
Income tax benefit	377	0	381	0
Net loss	(11,590)	(4,447)	(17,062)	(10,179)
Gain on extinguishment of Series A Convertible Preferred Stock	0	0	222	0
Net loss attributable to common stockholders	$ (12,152)	$ (5,552)	$ (17,701)	$ (18,694)
Basic and diluted net loss per common stock (in dollars per share)	$ (7.71)	$ (1,346.09)	$ (25.33)	$ (11,630.75)
Weighted-average number of common stock outstanding, basic and diluted (in shares)	1,575,762	4,125	698,877	1,607
Net loss	$ (11,590)	$ (4,447)	$ (17,062)	$ (10,179)
Change in cumulative translation adjustment	(163)	(92)	(282)	(37)
Total comprehensive loss attributable to common stockholders	(11,753)	(4,539)	(17,344)	(10,216)
Series A Preferred Stock [Member]
Other income (expense)
Deemed dividend on Preferred Stock	0	(1,105)	(299)	(8,392)
Series A Convertible Preferred Stock [Member]
Other income (expense)
Deemed dividend on Preferred Stock	(562)	0	(562)	0
Series C Preferred Stock [Member]
Other income (expense)
Deemed dividend on Preferred Stock	0	0	0	(123)
New September Warrants [Member]
Other income (expense)
Fair value modification to warrants	0	(4,189)	0	(4,189)
April & July 2023 Warrants [Member]
Other income (expense)
Fair value modification to warrants	$ 0	$ (591)	$ 0	$ (591)

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Redeemable Convertible Stockholders' Equity (Deficit) (Unaudited) - USD ($)	Total	Conversion of Debt into Series A Preferred Stock [Member]	April 2023 Warrants [Member]	Exchange Warrants [Member]	July 2023 Warrants [Member]	September 2023 Inducement Warrants [Member]	New September Warrants [Member]	April Pubic Offering [Member]	July 2023 Financing [Member]	Reverse Stock Split, 1 for 30 [Member]	Conversion of Preferred Stock Into Common Stock [Member]	Conversion of Series A Preferred Stock To Common Stock [Member]	Conversion of Series C into Series A Preferred Stock [Member]	Series A Convertible Preferred Stock [Member]	Series A Convertible Preferred Stock [Member] Conversion of Preferred Stock Into Common Stock [Member]	Series B Preferred Stock [Member]	Series B Preferred Stock [Member] Conversion of Preferred Stock Into Common Stock [Member]	Series C Preferred Stock [Member]	Series C Preferred Stock [Member] Conversion of Preferred Stock Into Common Stock [Member]	Series A Preferred Stock [Member]	Series A Preferred Stock [Member] July 10, 2023 Modification [Member]	Series A Preferred Stock [Member] September 14, 2023 Modification [Member]	Series A Preferred Stock [Member] Conversion of Debt into Series A Preferred Stock [Member]	Series A Preferred Stock [Member] Conversion of Series C into Series A Preferred Stock [Member]	Preferred Stock [Member]	Preferred Stock [Member] Exchange Warrants [Member]	Preferred Stock [Member] Reverse Stock Split, 1 for 30 [Member]	Preferred Stock [Member] Conversion of Preferred Stock Into Common Stock [Member]	Preferred Stock [Member] Series A Convertible Preferred Stock [Member]	Preferred Stock [Member] Series A Convertible Preferred Stock [Member] Exchange Warrants [Member]	Preferred Stock [Member] Series A Convertible Preferred Stock [Member] Reverse Stock Split, 1 for 30 [Member]	Preferred Stock [Member] Series A Convertible Preferred Stock [Member] Conversion of Preferred Stock Into Common Stock [Member]	Preferred Stock [Member] Series A Convertible Preferred Stock [Member] Conversion of Series A Preferred Stock To Common Stock [Member]	Preferred Stock [Member] Series A Convertible Preferred Stock [Member] Conversion of Series C into Series A Preferred Stock [Member]	Preferred Stock [Member] Series B Preferred Stock [Member]	Preferred Stock [Member] Series B Preferred Stock [Member] Conversion of Series A Preferred Stock To Common Stock [Member]	Preferred Stock [Member] Series B Preferred Stock [Member] Conversion of Series C into Series A Preferred Stock [Member]	Preferred Stock [Member] Series C Preferred Stock [Member]	Preferred Stock [Member] Series C Preferred Stock [Member] Conversion of Series A Preferred Stock To Common Stock [Member]	Preferred Stock [Member] Series C Preferred Stock [Member] Conversion of Series C into Series A Preferred Stock [Member]	Preferred Stock [Member] Series A Preferred Stock [Member]	Preferred Stock [Member] Series A Preferred Stock [Member] July 10, 2023 Modification [Member]	Preferred Stock [Member] Series A Preferred Stock [Member] September 14, 2023 Modification [Member]	Preferred Stock [Member] Series A Preferred Stock [Member] Conversion of Debt into Series A Preferred Stock [Member]	Preferred Stock [Member] Series A Preferred Stock [Member] April 2023 Warrants [Member]	Preferred Stock [Member] Series A Preferred Stock [Member] July 2023 Warrants [Member]	Preferred Stock [Member] Series A Preferred Stock [Member] September 2023 Inducement Warrants [Member]	Preferred Stock [Member] Series A Preferred Stock [Member] New September Warrants [Member]	Preferred Stock [Member] Series A Preferred Stock [Member] April Pubic Offering [Member]	Preferred Stock [Member] Series A Preferred Stock [Member] July 2023 Financing [Member]	Preferred Stock [Member] Series A Preferred Stock [Member] Reverse Stock Split, 1 for 30 [Member]	Preferred Stock [Member] Series A Preferred Stock [Member] Conversion of Series A Preferred Stock To Common Stock [Member]	Preferred Stock [Member] Series A Preferred Stock [Member] Conversion of Series C into Series A Preferred Stock [Member]	Common Stock [Member]	Common Stock [Member] July 10, 2023 Modification [Member]	Common Stock [Member] September 14, 2023 Modification [Member]	Common Stock [Member] Conversion of Debt into Series A Preferred Stock [Member]	Common Stock [Member] April 2023 Warrants [Member]	Common Stock [Member] Exchange Warrants [Member]	Common Stock [Member] July 2023 Warrants [Member]	Common Stock [Member] September 2023 Inducement Warrants [Member]	Common Stock [Member] New September Warrants [Member]	Common Stock [Member] April Pubic Offering [Member]	Common Stock [Member] July 2023 Financing [Member]	Common Stock [Member] Reverse Stock Split [Member]	Common Stock [Member] Reverse Stock Split, 1 for 30 [Member]	Common Stock [Member] Reverse Stock Split, 1 for 40 [Member]	Common Stock [Member] Conversion of Preferred Stock Into Common Stock [Member]	Common Stock [Member] Conversion of Series A Preferred Stock To Common Stock [Member]	Common Stock [Member] Conversion of Series C into Series A Preferred Stock [Member]	Common Stock [Member] Series A Preferred Stock [Member]	Additional Paid-in Capital [Member]	Additional Paid-in Capital [Member] Conversion of Debt into Series A Preferred Stock [Member]	Additional Paid-in Capital [Member] April 2023 Warrants [Member]	Additional Paid-in Capital [Member] Exchange Warrants [Member]	Additional Paid-in Capital [Member] July 2023 Warrants [Member]	Additional Paid-in Capital [Member] September 2023 Inducement Warrants [Member]	Additional Paid-in Capital [Member] New September Warrants [Member]	Additional Paid-in Capital [Member] April Pubic Offering [Member]	Additional Paid-in Capital [Member] July 2023 Financing [Member]	Additional Paid-in Capital [Member] Reverse Stock Split, 1 for 30 [Member]	Additional Paid-in Capital [Member] Conversion of Preferred Stock Into Common Stock [Member]	Additional Paid-in Capital [Member] Conversion of Series A Preferred Stock To Common Stock [Member]	Additional Paid-in Capital [Member] Conversion of Series C into Series A Preferred Stock [Member]	Additional Paid-in Capital [Member] Series B Preferred Stock [Member]	Additional Paid-in Capital [Member] Series C Preferred Stock [Member]	Additional Paid-in Capital [Member] Series A Preferred Stock [Member]	Additional Paid-in Capital [Member] Series A Preferred Stock [Member] July 10, 2023 Modification [Member]	Additional Paid-in Capital [Member] Series A Preferred Stock [Member] September 14, 2023 Modification [Member]	Additional Paid-in Capital [Member] Series A Preferred Stock [Member] Conversion of Series C into Series A Preferred Stock [Member]	AOCI Attributable to Parent [Member]	AOCI Attributable to Parent [Member] Conversion of Debt into Series A Preferred Stock [Member]	AOCI Attributable to Parent [Member] April 2023 Warrants [Member]	AOCI Attributable to Parent [Member] Exchange Warrants [Member]	AOCI Attributable to Parent [Member] July 2023 Warrants [Member]	AOCI Attributable to Parent [Member] September 2023 Inducement Warrants [Member]	AOCI Attributable to Parent [Member] New September Warrants [Member]	AOCI Attributable to Parent [Member] April Pubic Offering [Member]	AOCI Attributable to Parent [Member] July 2023 Financing [Member]	AOCI Attributable to Parent [Member] Reverse Stock Split, 1 for 30 [Member]	AOCI Attributable to Parent [Member] Conversion of Preferred Stock Into Common Stock [Member]	AOCI Attributable to Parent [Member] Conversion of Series A Preferred Stock To Common Stock [Member]	AOCI Attributable to Parent [Member] Conversion of Series C into Series A Preferred Stock [Member]	AOCI Attributable to Parent [Member] Series B Preferred Stock [Member]	AOCI Attributable to Parent [Member] Series C Preferred Stock [Member]	AOCI Attributable to Parent [Member] Series A Preferred Stock [Member] July 10, 2023 Modification [Member]	AOCI Attributable to Parent [Member] Series A Preferred Stock [Member] September 14, 2023 Modification [Member]	Retained Earnings [Member]	Retained Earnings [Member] Conversion of Debt into Series A Preferred Stock [Member]	Retained Earnings [Member] April 2023 Warrants [Member]	Retained Earnings [Member] Exchange Warrants [Member]	Retained Earnings [Member] July 2023 Warrants [Member]	Retained Earnings [Member] September 2023 Inducement Warrants [Member]	Retained Earnings [Member] New September Warrants [Member]	Retained Earnings [Member] April Pubic Offering [Member]	Retained Earnings [Member] July 2023 Financing [Member]	Retained Earnings [Member] Reverse Stock Split, 1 for 30 [Member]	Retained Earnings [Member] Conversion of Preferred Stock Into Common Stock [Member]	Retained Earnings [Member] Conversion of Series A Preferred Stock To Common Stock [Member]	Retained Earnings [Member] Conversion of Series C into Series A Preferred Stock [Member]	Retained Earnings [Member] Series B Preferred Stock [Member]	Retained Earnings [Member] Series C Preferred Stock [Member]	Retained Earnings [Member] Series A Preferred Stock [Member] July 10, 2023 Modification [Member]	Retained Earnings [Member] Series A Preferred Stock [Member] September 14, 2023 Modification [Member]
Balance (in shares) at Dec. 31, 2022																													13,586						190,786			0			0													19
Balance at Dec. 31, 2022	$ (113,000)																												$ 2,001,000						$ 2,000			$ 0			$ 0													$ 0																		$ 83,158,000																			$ (721,000)																	$ (82,550,000)
Issuance of stock (in shares)																																						50,000
Issuance of stock																		$ 0																				$ 1,160,000																																																$ 0																			$ 0																	$ 0
Deemed dividend of 5% and accretion of Series C Convertible Preferred Stock to redemption value																																						$ 167,000
Deemed dividend of 5% and accretion of Series C Convertible Preferred Stock to redemption value																		(167,000)																																																																				(167,000)																			0																	0
Reverse split (in shares)																																																																	1
Conversion of stock, converted (in shares)															(3,838)		0		0	(3,838)
Conversion of stock, converted															$ (565,000)		$ 0		$ 0																						0																																														$ 575,000
Conversion of stock (in shares)																																																																				30
Conversion of stock											$ 565,000																																																									$ 0														$ 565,000																			$ 0																	$ 0
Redemption of Series B Preferred Stock (in shares)																																			(190,786)
Redemption of Series B Preferred Stock																$ 2,000																			$ (2,000)																																																		$ 2,000																			$ 0																	$ 0
Stock based compensation (recoveries)	(121,000)																																								0													0																		(121,000)																			0																	0
Currency translation adjustment	84,000																																								0													0																		0																			84,000																	0
Net loss	(3,352,000)																																								$ 0													$ 0																		0																			0																	(3,352,000)
Balance (in shares) at Mar. 31, 2023																													9,748						0			50,000			0													50
Balance at Mar. 31, 2023	(3,102,000)																												$ 1,436,000						$ 0			$ 1,327,000			$ 0													$ 0																		83,437,000																			(637,000)																	(85,902,000)
Redemption of shares (in shares)																																			190,786
Reverse split (in shares)																																																																	(1)
Currency translation adjustment	(84,000)																																								$ 0													$ 0																		0																			(84,000)																	0
Redemption shares (in shares)																																			190,786
Redemption of convertible redeemable preferred stock																$ 2,000																			$ (2,000)																																																		$ 2,000																			$ 0																	$ 0
Balance (in shares) at Dec. 31, 2022																													13,586						190,786			0			0													19
Balance at Dec. 31, 2022	(113,000)																												$ 2,001,000						$ 2,000			$ 0			$ 0													$ 0																		83,158,000																			(721,000)																	(82,550,000)
Conversion of stock, converted (in shares)												(12,052)
Conversion of stock, converted														$ (3,899,000)
Net loss	(10,179,000)
Balance (in shares) at Sep. 30, 2023																													0						0			0			1,417													6,977
Balance at Sep. 30, 2023	(3,379,000)																												$ 0						$ 0			$ 0			$ 1,742,000													$ 0																		88,366,000																			(758,000)																	(92,729,000)
Balance (in shares) at Mar. 31, 2023																													9,748						0			50,000			0													50
Balance at Mar. 31, 2023	(3,102,000)																												$ 1,436,000						$ 0			$ 1,327,000			$ 0													$ 0																		83,437,000																			(637,000)																	(85,902,000)
Issuance of stock (in shares)																																																	0														416
Issuance of stock								$ 6,815,000																																									$ 0														$ 0																$ 6,815,000																			$ 0																	$ 0
Deemed dividend of 5% and accretion of Series C Convertible Preferred Stock to redemption value																																						$ 119,000
Deemed dividend of 5% and accretion of Series C Convertible Preferred Stock to redemption value																		$ (119,000)																																																																				$ (119,000)																			$ 0																	$ 0
Reverse split (in shares)																																																					5,577														1			0
Conversion of stock, converted (in shares)																				(8,214)				(50,000)									(5,509)	0		0	0		0	(50,000)
Conversion of stock, converted																																	$ (812,000)	$ 0		$ 0	$ 0		$ 0	$ (1,446,000)	(2,522,000)																																														3,334,000
Conversion of stock (in shares)																							486																					486								(2,705)					0												374
Conversion of stock		$ 453,000										$ 812,000	$ 1,447,000																															$ 453,000								$ (2,522,000)	$ 5,199,000				$ 0												$ 0	$ 0			$ 0										$ 3,334,000	$ (3,752,000)						$ (3,959,000)		$ 0										$ 0	$ 0						$ 0										$ 0	$ 0
Redemption of Series B Preferred Stock (in shares)																				(1,550)
Redemption of Series B Preferred Stock																																									(1,445,000)
Stock based compensation (recoveries)	180,000																																								0													0																		180,000																			0																	0
Currency translation adjustment	(29,000)																																								0													0																		0																			(29,000)																	0
Net loss	(2,380,000)																																								$ 0													$ 0																		0																			0																	(2,380,000)
Balance (in shares) at Jun. 30, 2023																													0						0			0			6,047													841
Balance at Jun. 30, 2023	(723,000)																												$ 0						$ 0			$ 0			$ 5,637,000													$ 0																		82,588,000																			(666,000)																	(88,282,000)
Fair value of April Warrants allocated to liabilities, net of financing costs			$ (3,772,000)																																										$ 0													$ 0																$ (3,772,000)																			$ 0																	$ 0
Elimination of Series A redemption rights (in shares)																													(4,239)												(4,239)													0
Elimination of Series A redemption rights	624,000																												$ (624,000)												$ 3,952,000													$ 0																		(3,328,000)																			0																	0
Elimination of Series A redemption rights (in shares)																													4,239												4,239													0
Redemption of Series A Preferred Stock for cancellation of debt (in shares)																																												(1,550)													0
Redemption of Series A Preferred Stock for cancellation of debt		$ (1,652,000)																																										$ (1,445,000)													$ 0																$ (207,000)																			$ 0																	$ 0
Redemption of shares (in shares)																				1,550
Reverse split (in shares)																																																					(5,577)														(1)			0
Currency translation adjustment	29,000																																								$ 0													$ 0																		0																			29,000																	0
Redemption shares (in shares)																				1,550
Redemption of convertible redeemable preferred stock																																									$ (1,445,000)
Issuance of stock (in shares)																																																		0														4,075
Issuance of stock									$ 10,080,000																																									$ 0														$ 0																$ 10,080,000																			$ 0																	$ 0
Redemption of Series B Preferred Stock (in shares)																				(4,630)																					4,630													(2,063)
Redemption of Series B Preferred Stock	(5,000,000)																																								$ (4,474,000)													$ 0																		(526,000)															(526,000)				0																	0
Stock based compensation (recoveries)	124,000																																								0													0																		124,000																			0																	0
Currency translation adjustment	(92,000)																																								0													0																		0																			(92,000)																	0
Net loss	(4,447,000)																																								$ 0													$ 0																		0																			0																	(4,447,000)
Balance (in shares) at Sep. 30, 2023																													0						0			0			1,417													6,977
Balance at Sep. 30, 2023	$ (3,379,000)																												$ 0						$ 0			$ 0			$ 1,742,000													$ 0																		88,366,000																			(758,000)																	(92,729,000)
Fair value of April Warrants allocated to liabilities, net of financing costs					$ (6,254,000)																																									$ 0														$ 0																$ (6,254,000)																			$ 0																	$ 0
Modification of shares																					$ 0	$ 0																				$ 206,000	$ 373,000												$ 0	$ 0																																$ (206,000)	$ (373,000)																	$ 0	$ 0																$ 0	$ 0
Redemption of shares (in shares)																				4,630																					(4,630)													2,063
Common share adjustment as a result of stock splits (in shares)	(2)
Warrants exercised						$ 1,238,000	$ 1,056,000																																								$ 0	$ 0													$ 0	$ 0															$ 1,238,000	$ 1,056,000																		$ 0	$ 0																$ 0	$ 0
Obligation to issue shares as a result of September 2023 warrant inducement						$ 639,000																																									$ 0														$ 0																$ 639,000																			$ 0																	$ 0
Currency translation adjustment	$ 92,000																																								$ 0													$ 0																		0																			92,000																	0
Redemption shares (in shares)																				4,630																					(4,630)													2,063
Redemption of convertible redeemable preferred stock	(5,000,000)																																								$ (4,474,000)													$ 0																		(526,000)															(526,000)				0																	0
Balance (in shares) at Dec. 31, 2023																													1,417												0													9,812
Balance at Dec. 31, 2023	(2,751,000)																								$ 0				$ 1,742,000												$ 0																															90,369,000																			(411,000)																	(94,451,000)
Issuance of stock (in shares)																													0												0													227
Issuance of stock	40,000																																																																							40,000																			0																	0
Deemed dividend of 5% and accretion of Series C Convertible Preferred Stock to redemption value																													$ 228,000
Deemed dividend of 5% and accretion of Series C Convertible Preferred Stock to redemption value	0																																																																							(228,000)																			0																	0
Reverse split (in shares)																													0																						0															1
Conversion of stock, converted (in shares)																				(202)
Conversion of stock, converted																																									$ (269,000)																														$ 0																269,000
Conversion of stock (in shares)																																(202)																																				904
Conversion of stock											0																	$ 0				$ (269,000)																																																		269,000																			0																	0
Stock based compensation (recoveries)	(32,000)																								0				$ 0												0																															(32,000)																			0																	0
Currency translation adjustment	(25,000)																								0				0												0																															0																			(25,000)																	0
Net loss	(3,843,000)																								0				$ 0												$ 0																															0																			0																	(3,843,000)
Balance (in shares) at Mar. 31, 2024																													1,215												0													11,426
Balance at Mar. 31, 2024	(6,471,000)																								0				$ 1,510,000												$ 0																															90,699,000																			(386,000)																	(98,294,000)
Extinguishment of preferred stock	0																												$ (191)																																											191,000
Shares issued for compensation (in shares)																													0												0													484
Shares issued for compensation	90,000																								0				$ 0												$ 0																															90,000																			0																	0
Reverse split (in shares)																													0																						0															(1)
Currency translation adjustment	25,000																								0				$ 0												$ 0																															0																			25,000																	0
Balance (in shares) at Dec. 31, 2023																													1,417												0													9,812
Balance at Dec. 31, 2023	(2,751,000)																								0				$ 1,742,000												$ 0																															90,369,000																			(411,000)																	(94,451,000)
Conversion of stock, converted (in shares)												(1,417)
Balance (in shares) at Jun. 30, 2024																													0												0													1,167,974
Balance at Jun. 30, 2024	19,835,000																								3,000				$ 0												$ 0																															120,285,000																			(530,000)																	(99,923,000)
Balance (in shares) at Dec. 31, 2023																													1,417												0													9,812
Balance at Dec. 31, 2023	(2,751,000)																								0				$ 1,742,000												$ 0																															90,369,000																			(411,000)																	(94,451,000)
Conversion of stock, converted (in shares)												(1,417)
Conversion of stock, converted														$ (1,819,000)
Net loss	(17,062,000)
Balance (in shares) at Sep. 30, 2024																													0												0													2,759,070
Balance at Sep. 30, 2024	12,964,000																								0				$ 0												$ 0																															125,170,000																			(693,000)																	(111,513,000)
Warrants exercised				$ 400,000
Balance (in shares) at Mar. 31, 2024																													1,215												0													11,426
Balance at Mar. 31, 2024	(6,471,000)																								0				$ 1,510,000												$ 0																															90,699,000																			(386,000)																	(98,294,000)
Issuance of stock (in shares)																																																						1,062,822
Issuance of stock	27,652,000																								3,000																																															27,649,000																			0																	0
Deemed dividend of 5% and accretion of Series C Convertible Preferred Stock to redemption value																													71,000
Deemed dividend of 5% and accretion of Series C Convertible Preferred Stock to redemption value	0																																																																							(71,000)																			0																	0
Reverse split (in shares)																															0																				0															1
Conversion of stock, converted (in shares)																				(1,215)
Conversion of stock, converted																																									(1,550,000)																														0																$ 1,550,000
Conversion of stock (in shares)																																(1,215)																																				15,072
Conversion of stock											$ 0																	$ 0				$ (1,550,000)																																																		$ 1,550,000																			$ 0																	$ 0
Stock based compensation (recoveries)	22,000																								0				0												0																															22,000																			0																	0
Currency translation adjustment	144,000																								0				0												0																															0																			144,000																	0
Net loss	(1,629,000)																								0				$ 0												$ 0																															0																			0																	(1,629,000)
Balance (in shares) at Jun. 30, 2024																													0												0													1,167,974
Balance at Jun. 30, 2024	19,835,000																								3,000				$ 0												$ 0																															120,285,000																			(530,000)																	(99,923,000)
Extinguishment of preferred stock	0																												(31,000)																																											31,000																			0																	0
Reverse split (in shares)																															0																				0															(1)
Currency translation adjustment	(144,000)																								0				0												$ 0																															0																			(144,000)																	0
Cashless exercise of 3i Exchange Warrants (in shares)																														0																													78,655
Cashless exercise of 3i Exchange Warrants				$ 405,000																						$ 0				$ 0																																													$ 405,000																			$ 0																	$ 0
Issuance of stock (in shares)																																									35,000													1,493,878
Issuance of stock	5,427,000																								0																$ 2,938,000																														$ 2,938,000	5,427,000																			0																	0
Deemed dividend of 5% and accretion of Series C Convertible Preferred Stock to redemption value																																									$ 562,000
Deemed dividend of 5% and accretion of Series C Convertible Preferred Stock to redemption value	0																																																																							(562,000)																			0																	0
Reverse split (in shares)																																																																		97,218
Redemption of Series B Preferred Stock (in shares)																																									35,000
Redemption of Series B Preferred Stock	(3,500,000)																																								$ (3,500,000)																															0																			0																	0
Stock based compensation (recoveries)	17,000																								0				0												0																															17,000																			0																	0
Currency translation adjustment	163,000																								0				0												0																															0																			163,000																	0
Net loss	(11,590,000)																								0				$ 0												$ 0																															0																			0																	(11,590,000)
Balance (in shares) at Sep. 30, 2024																													0												0													2,759,070
Balance at Sep. 30, 2024	12,964,000																								0				$ 0												$ 0																															125,170,000																			(693,000)																	(111,513,000)
Redemption of shares (in shares)																																									(35,000)
Reverse split (in shares)																																																																		(97,218)
Currency translation adjustment	(163,000)																								$ 0				$ 0												$ 0																															0																			(163,000)																	0
Redemption shares (in shares)																																									(35,000)
Redemption of convertible redeemable preferred stock	$ (3,500,000)																																								$ (3,500,000)																															$ 0																			$ 0																	$ 0
Reverse split										$ 0																	$ (3,000)				$ 0																				$ 0																														$ 3,000																			$ 0																	$ 0

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Changes in Redeemable Convertible Stockholders' Equity (Deficit) (Unaudited) (Parentheticals)	3 Months Ended
	Mar. 31, 2023
Series C Preferred Stock [Member]
Dividend percent	5%

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Cash Flows from Operating Activities:
Net loss	$ (17,062)	$ (10,179)
Reconciliation of net loss to net cash used in operating activities:
Depreciation and amortization	8	28
Stock-based compensation	7	183
Impairment of intangible assets	9,703	0
Unrealized foreign exchange (gains) losses	(10)	88
Non-cash financing cost	0	1,110
Non-cash interest	173	230
Change in fair value of warrant and derivative liabilities	(2,676)	(7,187)
Deferred income taxes	(446)	0
Changes in operating assets and liabilities:
Other current assets	109	530
Tax credit receivable	(837)	(774)
Prepaid expenses	630	195
Accounts payable	(3,623)	96
Accrued liabilities	(123)	(152)
Income taxes payable	1	(13)
Operating lease liability	0	(8)
Net cash used in operating activities	(14,146)	(11,073)
Cash Flows from Financing Activities:
Proceeds from ATM sales of common stock, net of issuance costs	33,119	0
Net proceeds from sale of common stock and pre-funded warrant issuance	0	16,895
Net proceeds from warrants exercised in conjunction with price & warrant inducement	0	1,720
Proceeds from 3i promissory notes	1,340	1,050
Repayment of 3i debt and promissory notes	(1,340)	(3,698)
Net cash provided by financing activities	32,557	10,473
Net increase (decrease) in cash and cash equivalents	18,411	(600)
Effect of exchange rate changes on cash and cash equivalents	(114)	(30)
Cash and cash equivalents, beginning of period	166	2,029
Cash and cash equivalents, end of period	18,463	1,399
Supplemental disclosure of cash flow information:
Cash paid for income taxes	0	6
Cash paid for interest	408	36
Supplemental disclosure of non-cash financing and investing activities:
Stock issued in conjunction with consulting agreement	90	0
Issuance of 2,359,650 common shares on conversion of 3,632,366 3i Exchange Warrants	405	0
Issuance of Series A Preferred Stock To Extinguish 3i Note [Member]
Supplemental disclosure of non-cash financing and investing activities:
Issuance of Series A Preferred Stock to extinguish $350 3i Promissory Note	0	453
Conversion of Series C Preferred Stock To Series A Preferred Stock [Member]
Supplemental disclosure of non-cash financing and investing activities:
Issuance of Series A Preferred Stock in Exchange for Series C Preferred Stock	0	5,199
Elimination of Series A Redemption Rights [Member]
Supplemental disclosure of non-cash financing and investing activities:
Deemed Dividend	0	3,328
Conversion of Series C into Series A Preferred Stock [Member]
Supplemental disclosure of non-cash financing and investing activities:
Deemed Dividend	0	3,752
Redemption of Series A Preferred Stock [Member]
Supplemental disclosure of non-cash financing and investing activities:
Deemed Dividend	0	207
Series C Convertible Preferred Stock [Member]
Cash Flows from Financing Activities:
Proceeds from Preferred Stock issuance	0	1,160
Supplemental disclosure of non-cash financing and investing activities:
Deemed Dividend	0	123
Series B Preferred Stock [Member]
Cash Flows from Financing Activities:
Repurchase of preferred stock	0	(2)
Series A Convertible Preferred Stock [Member]
Cash Flows from Financing Activities:
Proceeds from Preferred Stock issuance	2,938	0
Repurchase of preferred stock	(3,500)	0
Supplemental disclosure of non-cash financing and investing activities:
Conversion of Series A Redeemable Preferred Stock	1,819	3,899
Deemed Dividend	562	0
Series A Preferred Stock [Member]
Cash Flows from Financing Activities:
Repurchase of preferred stock	0	(6,652)
Supplemental disclosure of non-cash financing and investing activities:
Deemed Dividend	(299)	8,392
Gain on extinguishment of Series A Preferred Stock	222	0
New September Warrants [Member]
Reconciliation of net loss to net cash used in operating activities:
Fair value modification to warrants	0	4,189
April & July 2023 Warrants [Member]
Reconciliation of net loss to net cash used in operating activities:
Fair value modification to warrants	$ 0	$ 591

Note 1 - Organization, Principa

Note 1 - Organization, Principal Activities and Basis of Presentation	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. Background Allarity Therapeutics, Inc. and Subsidiaries (the “Company”) is a clinical stage pharmaceutical company that develops drugs for the personalized treatment of cancer using drug specific companion diagnostics generated by its proprietary drug response predictor technology, DRP®. Additionally, the Company, through its Danish subsidiary, Allarity Therapeutics Europe ApS (previously Oncology Venture ApS), specializes in the research and development of anti-cancer drugs. The Company’s principal operations are located at Venlighedsvej 1, 2970 24 2 nd 02108. Liquidity The accompanying unaudited condensed interim consolidated financial statements (the “Financial Statements”) have been prepared on the basis of continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. Pursuant to the requirements of Accounting Standard Codification (ASC) 205 40, one As a biopharmaceutical organization, the Company has devoted substantially all of its resources since inception to research and development activities for its Drug Response Predictor “DRP” in conjunction with the Company's product candidate, business planning, raising capital, establishing its intellectual property portfolio, acquiring or discovering new product candidates, and providing general and administrative support for these operations. As a result, the Company has incurred significant operating losses and negative cash flows from operations since its inception and anticipates such losses and negative cash flows will continue for the foreseeable future. Since inception the Company has funded its operations primarily from sales of its stock. The Company has incurred significant losses and has an accumulated deficit of $111.5 million as of September 30, 2024 not September 30, 2024 12 While the Company believes its capital resources are sufficient to fund the Company’s on-going operations for the next 12 1 third 2 3 4 may not Basis of Presentation The Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) as established by the Financial Accounting Standards Board (the “FASB”) for interim financial information and the rules and regulations of the Securities and Exchange Commission (the “SEC”). The Financial Statements contain all normal and recurring adjustments necessary to state fairly the consolidated balance sheet, results of operations and comprehensive loss, statements of changes in redeemable convertible preferred stock and stockholders’ equity (deficit), and cash flows of the Company for the interim periods presented. Except as otherwise disclosed, all such adjustments consist only of those of a normal recurring nature. Operating results for the three nine September 30, 2024 not may December 31, 2024 not December 31, 2023 10 10 March 8, 2024. Use of Estimates The preparation of Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amount of assets and disclosure of contingent assets and liabilities at the date of the unaudited interim condensed consolidated financial statements and the reported amounts of revenue and expenses during the reported period. Actual results could differ from these estimates and assumptions.

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Significant Accounting Policies [Text Block]	2. There have been no 10 December 31, 2023, Organization and Principles of Consolidation All intercompany transactions and balances, including unrealized profits from intercompany sales, have been eliminated upon consolidation. Foreign currency and currency translation The functional currency is the currency of the primary economic environment in which an entity’s operations are conducted. The Company and its subsidiaries operate mainly in Denmark and the United States. The functional currencies of the Company’s subsidiaries are their local currency. The Company’s reporting currency is the U.S. dollar. The Company translates the assets and liabilities of its Denmark subsidiaries into the U.S. dollar at the exchange rate in effect on the balance sheet date. Revenues and expenses are translated at the average exchange rate in effect during each monthly period. Unrealized translation gains and losses are recorded as a cumulative translation adjustment, which is included in the condensed consolidated statements of changes in stockholders’ equity (deficit) as a component of accumulated other comprehensive loss. Monetary assets and liabilities denominated in currencies other than the functional currency are remeasured into the functional currency at rates of exchange prevailing at the balance sheet dates. Non-monetary assets and liabilities denominated in foreign currencies are re-measured into the functional currency at the exchange rates prevailing at the date of the transaction. Exchange gains or losses arising from foreign currency transactions are included in the determination of net loss for the respective periods. Adjustments that arise from exchange rate translations are included in other comprehensive loss in the condensed consolidated statements of operations and comprehensive loss as incurred. Adjustments that arise from exchange rate translations are included in other comprehensive loss in the consolidated statements of operations and comprehensive loss as incurred. During the three September 30, 2024 2023 nine September 30, 2024 2023 Concentrations of credit risk and of significant suppliers Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains its cash and cash equivalents in financial institutions in amounts that could exceed government-insured limits. The Company does not not not third Cash and cash equivalents The Company considers all highly liquid investments with a maturity of three may not Accumulated other comprehensive loss Accumulated other comprehensive loss includes net loss as well as other changes in stockholders’ equity (deficit) that result from transactions and economic events other than those with shareholders. The Company records unrealized gains and losses related to foreign currency translation and instrument specific credit risk as components of other accumulated comprehensive loss in the condensed consolidated statements of operations and comprehensive loss. During the three nine September 30, 2024 2023 Recently Issued Accounting Pronouncements Changes to U.S. GAAP are established by the FASB in the form of accounting standards updates (“ASUs”) to the FASB’s Accounting Standards Codification. The Company considers the applicability and impact of all ASUs. All ASUs issued through the date of the Financial Statements were assessed and determined not Accounting Standards Not In November 2023, No. 2023 07, Segment Reporting (Topic 280 280, December 15, 2023, December 15, 2024. In December 2023, No. 2023 09, Income Taxes (Topic 740 December 15, 2024. In November 2024, No. 2024 03, Income Statement Reporting Comprehensive Income Expense Disaggregation Disclosures (Subtopic 220 40 not December 15, 2026, December 15, 2027.

Note 3 - Intangible Assets

Note 3 - Intangible Assets	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Intangible Assets Disclosure [Text Block]	3. The Company’s IPR&D assets have been classified as indefinite-lived intangible assets. The Company’s individual material development project in progress, stenoparib, is recorded at $0 September 30, 2024 December 31, 2023 The Company has halted enrollment in the ongoing Phase 2 26%. three September 30, 2024, no 2023.

Note 4 - Accrued Liabilities

Note 4 - Accrued Liabilities	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	4. The Company’s accrued liabilities are comprised of the following: September 30, December 31, ($ in thousands) 2024 2023 Development cost liability $ 105 $ 114 Accrued interest on milestone liabilities 237 101 Accrued audit and legal 652 425 Payroll accruals 233 398 Accrued contracted services and other 95 271 Total accrued expenses $ 1,322 $ 1,309

Note 5 - Convertible Promissory

Note 5 - Convertible Promissory Note Due to Novartis	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Convertible Promissory Note [Text Block]	5. On January 26, 2024, April 6, 2018, September 30, 2024

Note 6 - Convertible Senior Pro

Note 6 - Convertible Senior Promissory Notes Due to 3i, Lp (3i")	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Debt Disclosure [Text Block]	6. 3i, “3i” 3i ( 2024 2024 ) During the three March 31, 2024, 3i, three i. On January 18, 2024, January 18, 2025, ii. On February 13, 2024, February 13, 2025, iii. On March 14, 2024, March 14, 2025, The Company agreed to pay interest to 3i 2024 one 2024 3i’s 90% ten 2024 3i Redemption Subject to the provisions of the 2024 2024 one 3i may first 100% 2024 9 3i may The 2024 May 6, 2024. 3i 2023 On November 22, 2022, 3i, three November 28, 2022, 1 3i July 14, 2022; 2 December 30, 2022, Each Note matured on January 1, 2024, may six June 30, 2023, The 3i April 21, 2023.

Note 7 - Preferred Stock

Note 7 - Preferred Stock	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Preferred Stock [Text Block]	7. August 2024 On August 19, 2024 ( “August 2024 “August 2024 “August 2024 “August 2024 August 2024 August 2024 On the Closing Date, the Company filed a certificate of designation (the “August 2024 August 2024 August 2024 August 2024 August 2024 August 2024 August 2024 August 2024 The holders of the August 2024 August 2024 On the Closing Date, the Company and the August 2024 “August 2024 August 2024 August 30, 2024. All of the August 2024 September 2024. August 2024 three nine September 30, 2024. Series A Convertible Preferred Stock and Common Stock Purchase Warrants Amendments to Series A Convertible Preferred Stock Determination of Conversion Price Adjustments for Series A Preferred Stock On December 9, 2022, 3i “2022 8 3i five January 19, 2023. 3i, not On January 23, 2023, 3i 2022 five 3i. Modification to Conversion Price of Series A Preferred Stock and 3i On January 14, 2024, 3i December 31, 2023 January 14, 2024. January 14, 2024, January 14, 2024, January 14, 2024. January 14, 2024. On February 13, 2024, 3i January 18, 2024, February 13, 2024. February 14, 2024, On March 14, 2024, 3i February 13, 2024, March 14, 2024. March 14, 2024, During the period April 1, 2024, May 2, 2024, 2024 May 1, 2024. Accounting Series A Preferred Stock As a result of fair value adjustments during the nine September 30, 2024 nine September 30, 2024 January 14 – March 14, April 5 – May 2, 2024 2024 Initial exercise price 20.000 -8.1010 7.000 -1.1515 Stock price on valuation date 8.955 -7.1010 4.522 -1.2323 Risk-free rate 5.10% - 4.82% 5.47% - 5.49% Term (in years) 0.25 - 0.08 0.08 - 0.01 Rounded annual volatility 145% - 130% 110% 3i The 3i Series A Preferred Stock and 3i During the nine September 30, 2024 (a) 3i September 30, 2024 (b) 3i 3i September 30, 2024 3i During the nine September 30, 2023, 3i 3i September 30, 2023, The accounting for the Series A Preferred Stock and Warrants is illustrated in the tables below: Consolidated Statement of Operations & Comprehensive Consolidated Balance Sheets Loss Fair value Series A Convertible adjustment to Series A Redeemable Additional derivative Warrant Preferred Preferred paid-in and warrant ($ in thousands) liability Stock Stock capital liabilities Balances, December 31, 2023 $ 3,083 $ 1,742 — $ (7,208 ) $ — Conversion of 202 — (269 ) — 269 — Extinguishment of Series A Preferred Stock — (191 ) — 191 — Deemed dividend on January 14, 2024, modification — 228 — (228 ) — Fair value adjustment (419 ) — — — 419 Balances, March 31, 2024 2,664 1,510 — (6,976 ) 419 Conversion of 1,215 — (1,550 ) — 1,550 — Extinguishment of Series A Preferred Stock — (31 ) — 31 — Deemed dividend on modification of Series A Preferred Stock — 71 — (71 ) — Cashless exercise of 3i Exchange Warrants (405 ) — — 405 — Fair value adjustment (2,243 ) — — — 2,243 Balances, June 30, 2024 $ 16 $ — $ — $ (5,061 ) $ 2,662 Fair value adjustment (14 ) — — — 14 Issuance of redeemable preferred stock — — 2,938 — — Redemption of redeemable preferred stock — — (3,500 ) — — Deemed dividend on redeemable preferred stock — — 562 (562 ) — Balances, September 30, 2024 $ 2 $ — $ — $ (5,623 ) $ 2,676 Consolidated Statement of Operations & Comprehensive Consolidated Balance Sheets Loss Series A Preferred Fair value Convertible adjustment to Stock – Series A Additional derivative Warrant Mezzanine Preferred paid-in and warrant ($ in thousands) liability Equity Stock capital liabilities Balances, December 31, 2022 $ 374 $ 2,001 $ — $ (3,756 ) $ — Conversion of 3,838 — (565 ) — 575 — Fair value adjustment (309 ) — — — 309 Balances, March 31, 2023 65 1,436 — (3,181 ) 309 Conversion of 8,214 — (812 ) (2,522 ) 3,334 — Elimination of redemption rights on Series A Preferred stock; deemed dividend of $ 3,328 — (624 ) 3,952 (3,328 ) — Redemption of 1,550 — — (1,445 ) — — Issuance of 486 350 103 — — 453 — — Exchange of 50,000 5,577 3,959 — — 5,199 (3,959 ) — Fair value adjustment 1,078 — — — (1,078 ) Balances, June 30, 2023 $ 1,143 $ — $ 5,637 $ (7,134 ) $ (769 ) July 10, 2023 modification — — 206 (206 ) — Redemption of 4,630 — — (4,474 ) (526 ) — September 14, 2023 modification — — 373 (373 ) — Fair value adjustment 2,803 — — — (2,803 ) Balances, September 30, 2023 $ 3,946 $ — $ 1,742 $ (8,239 ) $ (3,572 ) Series C Convertible Preferred Stock On February 28, 2023, “2023 3i The Company evaluated the terms of the Series C Preferred Stock as required pursuant to ASC 570, 480, 815 2020 06, April 21, 2023, April 21, 2023, The Company treated the exchange of Series C Preferred Stock for Series A Preferred Stock as an extinguishment as there has been a fundamental change in the nature of the instrument and applied the derecognition accounting model in ASC 260 10 S99 2. 1 2

Note 8 - Derivative Liabilities

Note 8 - Derivative Liabilities	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Derivative Instruments and Hedging Activities Disclosure [Text Block]	8. Continuity of Common Share Purchase Warrant and 3i Warrant liabilities are categorized within Level 3 The Common Share Purchase Warrants, comprised of warrants issued in April 2023, July 2023, September 2023, 3i December 31, 2023, nine September 30, 2024, Common Share Purchase 3i Exchange ($ in thousands) Warrants Warrants Balance as of January 1, 2023 $ — $ 374 Issuance date fair value of April, July & September 2023 Common share purchase warrants 15,161 — Modifications to fair value upon exercise 592 — Change in fair value adjustment of derivative and warrant liabilities (11,911 ) 1,477 Amount transferred to Equity (1,579 ) (1,031 ) Balance as of December 31, 2023 $ 2,263 $ 820 Fair value per Common warrant / 3i Warrant / issuable at December 31, 2023 $ 264.60 $ 114.00 Common Share Purchase 3i Exchange ($ in thousands) Warrants Warrants Balance at January 1, 2024 $ 2,263 $ 820 Change in fair value adjustment of derivative and warrant liabilities (2,261 ) (415 ) Cashless conversion of 3i Exchange Warrants — (405 ) Balance at September 30, 2024 $ 2 $ — Fair value per Common warrant issuable at September 30, 2024 $ 0.28 $ — Common Share Purchase Warrants Valuation Inputs On September 30, 2024 September 2023 April 2023 July 2023 Inducement Warrants Warrants Warrants Initial exercise price $ 600.00 $ 600.00 $ 600.00 Stock price on valuation date $ 2.11 $ 2.11 $ 2.11 Risk-free rate 3.58 % 3.58 % 3.58 % Term (in years) 3.77 3.77 4.45 Rounded annual volatility 124 % 124 % 124 % 3i On September 30, 2023, 2 3i 3i September 30, 2023 September 30, 2023 Initial exercise price $ 600.00 Stock price on valuation date $ 450.00 Risk-free rate 5.22 % Expected life of the Warrant to convert (years) 1.22 Rounded annual volatility 152 % Timing of liquidity event Q4 - 2023 Expected probability of event 10 %

Note 9 - Stockholders' Equity

Note 9 - Stockholders' Equity	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Equity [Text Block]	9. Equity Common Stock On September 9, 2024, Reverse Stock Splits On April 4, 2024, 1 "April April 9, 2024. No April April April March 31, 2024, On September 9, 2024, 1 "September September 11, 2024. September September one September September 11, 2024, September 11, 2024. No September one September one one All share and per share information has been retroactively adjusted to give effect to the April September 2023 Shelf On November 2, 2023, No. 333 275282 3, November 29, 2023 ( September 30, 2024. ATM Facility On March 19, 2024, may 3 No. 333 275282 November 2, 2023 November 29, 2023, September 9, 2024 424 1933, May 2, 2024, not I.B.6 3. Under the Sales Agreement, Ascendiant may 415 4 may may For the three nine September 30, 2024, no 2023. Series A Preferred Stock During the six June 30, 2024, 3i June 30, 2024, Exchange Warrants 3i April 12, 2024, May 2, 2024. September 30, 2024 Settlement Agreement In accordance with the terms of the settlement agreement between the Company and James G. Cullem, the Company's former CEO, the Company issued 484 shares of common stock valued at $90,000 to James G. Cullem in exchange for consulting services for the nine September 30, 2024. Equity Incentive Plan The Company has in effect the Allarity Therapeutics, Inc. 2021 “2021 2021 2021 10 10 At the 2024 September 3, 2024, 2021 2021 The number of shares available for grant and issuance under the 2021 January 1 st 2022 2031, December 31 Total shares available for the issuance of stock-based awards under the Company’s 2021 September 30, 2024. The Company granted inducement awards consisting of 55,555 common shares on September 12, 2024 September 30, 2024. 5635 4 not 2021 Restricted Stock Units The following table summarizes the restricted stock unit activity during the nine September 30, 2024: Weighted Number of Average Grant Units Date Fair Value Unvested balance at December 31, 2023 — — Granted 174,038 $ 2.36 Unvested balance at September 30, 2024 174,038 $ 2.36 At September 30, 2024, Stock Options The following table summarizes stock option activity during the nine September 30, 2024: Weighted Average Weighted Remaining Aggregate Number Average Contractual Intrinsic Value of Options Exercise Price Term (years) (in thousands) Outstanding at December 31, 2023 9 $ 4,725,600 3.2 — Cancelled/forfeited (2 ) 2,606,960 — — Outstanding at September 30, 2024 7 $ 4,699,177 2.7 — Expected to vest 1 $ 924,000 3.0 — Exercisable 6 $ 5,328,373 2.6 — There were no options granted during the nine September 30, 2024. September 30, 2024, not Stock-based compensation expense has been reported in the Company's condensed consolidated statements of operations as follows: Three Months Ended Nine Months Ended September 30, September 30, ($ in thousands) 2024 2023 2024 2023 Research and development $ 11 $ 121 $ 8 $ 39 General and administrative 6 59 (1 ) 20 Total stock-based compensation expense $ 17 $ 180 $ 7 $ 59

Note 10 - License and Developme

Note 10 - License and Development Agreements	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
License And Development Agreements [Text Block]	10. License Agreement with Novartis for Dovitinib On January 26, 2024, September 30, 2024 License Agreement with Eisai Inc. for Stenoparib The Company holds the exclusive worldwide rights to all preventative, therapeutic and/or diagnostic uses related to cancer in humans and by amendment to the agreement on December 11, 2020, not six three three one Effective July 12, 2022, July 6, 2017 1 first 1b 2 December 31, 2022; 2 On May 26, 2023, fourth May 16, 2023, 1b 2 10 fourth March 1, 2024. On February 26, 2024, May 1, 2024, fifth one ten no September 1, 2024. August 20, 2024 no On August 2, 2024, sixth August 2, 2024. 1 2 Development Milestone Payments The Company has agreed to make milestone payments to Eisai in connection with the development of stenoparib by the Company or its affiliates, or by a third 2 first first 3 first may one first Royalty Payments In addition to the milestone payments described above, the Company has agreed to pay Eisai royalties based on annual incremental sales of product derived from stenoparib in an amount between 5% and 10% of annual sales of between $0 and $100 million, between 6% and 10% of annual sales between $100 million and $250 million, between 7% and 11% of annual sales between $250 million and $500 million, and between 11% and 15% of annual sales in excess of $500 million. The Company is obligated to pay royalties under the agreement on a country-by-country and product-by-product basis for a period that commences with the first 15 first may 120 not 90 30 Eisai also has the right to terminate the agreement upon written notice of a material breach of the agreement by the Company that is not 90 30 Option to Reacquire Rights to Stenoparib For the period commencing with enrollment of the first five 2 90 2 2 April 15, 2019, not

Note 11 - Related Party

Note 11 - Related Party	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	11. During the three nine September 30, 2024, June 1, 2024, During the three nine September 30, 2023,

Note 12 - Loss Per Share of Com

Note 12 - Loss Per Share of Common Stock	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Earnings Per Share [Text Block]	12. Basic loss per share is derived by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during each period. Diluted loss per share includes the effect, if any, of the potential exercise or conversion of securities, such as warrants and stock options, which would result in the issuance of incremental shares of common stock unless such effect is anti-dilutive. In calculating the basic and diluted net loss per share applicable to common stockholders, the weighted average number of shares remained the same for both calculations because when a net loss exists, dilutive shares are not As of September 30, 2024 2023 Warrants 8,557 27,369 Options 7 9 Unvested restricted stock units 174,038 — Series A Convertible Preferred stock — 2,551 182,602 29,929

Note 13 - Financial Instruments

Note 13 - Financial Instruments	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Financial Instruments Disclosure [Text Block]	13. The following tables present information about the Company’s financial instruments measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values: Fair Value Measurements as of September 30, 2024 ($ in thousands) Level 1 Level 2 Level 3 Total Liabilities: Warrant liability $ — $ — $ (2 ) $ (2 ) $ — $ — $ (2 ) $ (2 ) Fair Value Measurements as of December 31, 2023 ($ in thousands) Level 1 Level 2 Level 3 Total Liabilities: Warrant liability $ — $ — $ (2,263 ) $ (2,263 ) Derivative warrant liability — — (820 ) (820 ) $ — $ — $ (3,083 ) $ (3,083 ) Methods used to estimate the fair values of the Company's financial instruments, not When available, the Company’s marketable securities are valued using quoted prices for identical instruments in active markets. If the Company is unable to value its marketable securities using quoted prices for identical instruments in active markets, the Company values its investments using broker reports that utilize quoted market prices for comparable instruments. The Company has no 2 3 one The Company recognizes its derivative liabilities as Level 3 8. The Company reviews the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may 3, no 1 2 nine September 30, 2024 2023

Note 14 - Commitments and Conti

Note 14 - Commitments and Contingencies	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	14. Indemnification In accordance with its certificate of incorporation, bylaws, and indemnification agreements, the Company has indemnification obligations to its officers and directors for certain events or occurrences, subject to certain limits, while they are serving at the Company's request in such capacity. SEC Investigation On July 19, 2024, 2021. 2022. three Nasdaq Delisting Notifications On June 18, 2024, not 5550 2 30 $1 July 30, 2024, August 15, 2024, September 6, 2024 September 3, 2024. October 9, 2024, 5550 2 Class Action On September 13, 2024, Osman Mukeljic v. Allarity Therapeutics, Inc., et al 1:24 06952, 10 1934 10b 5 20 1934 no may

Note 15 - Subsequent Events

Note 15 - Subsequent Events	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Subsequent Events [Text Block]	15. For its Financial Statements as of September 30, 2024, three not ATM Facility During the period October 1, 2024 November 13, 2024,

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Sep. 30, 2024
Insider Trading Arr Line Items
Rule 10b5-1 Arrangement Adopted [Flag]	false
Non-Rule 10b5-1 Arrangement Adopted [Flag]	false
Rule 10b5-1 Arrangement Terminated [Flag]	false
Non-Rule 10b5-1 Arrangement Terminated [Flag]	false

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	Organization and Principles of Consolidation All intercompany transactions and balances, including unrealized profits from intercompany sales, have been eliminated upon consolidation.
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign currency and currency translation The functional currency is the currency of the primary economic environment in which an entity’s operations are conducted. The Company and its subsidiaries operate mainly in Denmark and the United States. The functional currencies of the Company’s subsidiaries are their local currency. The Company’s reporting currency is the U.S. dollar. The Company translates the assets and liabilities of its Denmark subsidiaries into the U.S. dollar at the exchange rate in effect on the balance sheet date. Revenues and expenses are translated at the average exchange rate in effect during each monthly period. Unrealized translation gains and losses are recorded as a cumulative translation adjustment, which is included in the condensed consolidated statements of changes in stockholders’ equity (deficit) as a component of accumulated other comprehensive loss. Monetary assets and liabilities denominated in currencies other than the functional currency are remeasured into the functional currency at rates of exchange prevailing at the balance sheet dates. Non-monetary assets and liabilities denominated in foreign currencies are re-measured into the functional currency at the exchange rates prevailing at the date of the transaction. Exchange gains or losses arising from foreign currency transactions are included in the determination of net loss for the respective periods. Adjustments that arise from exchange rate translations are included in other comprehensive loss in the condensed consolidated statements of operations and comprehensive loss as incurred. Adjustments that arise from exchange rate translations are included in other comprehensive loss in the consolidated statements of operations and comprehensive loss as incurred. During the three September 30, 2024 2023 nine September 30, 2024 2023
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentrations of credit risk and of significant suppliers Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains its cash and cash equivalents in financial institutions in amounts that could exceed government-insured limits. The Company does not not not third
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and cash equivalents The Company considers all highly liquid investments with a maturity of three may not
Comprehensive Income, Policy [Policy Text Block]	Accumulated other comprehensive loss Accumulated other comprehensive loss includes net loss as well as other changes in stockholders’ equity (deficit) that result from transactions and economic events other than those with shareholders. The Company records unrealized gains and losses related to foreign currency translation and instrument specific credit risk as components of other accumulated comprehensive loss in the condensed consolidated statements of operations and comprehensive loss. During the three nine September 30, 2024 2023
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Issued Accounting Pronouncements Changes to U.S. GAAP are established by the FASB in the form of accounting standards updates (“ASUs”) to the FASB’s Accounting Standards Codification. The Company considers the applicability and impact of all ASUs. All ASUs issued through the date of the Financial Statements were assessed and determined not Accounting Standards Not In November 2023, No. 2023 07, Segment Reporting (Topic 280 280, December 15, 2023, December 15, 2024. In December 2023, No. 2023 09, Income Taxes (Topic 740 December 15, 2024. In November 2024, No. 2024 03, Income Statement Reporting Comprehensive Income Expense Disaggregation Disclosures (Subtopic 220 40 not December 15, 2026, December 15, 2027.

Note 4 - Accrued Liabilities (T

Note 4 - Accrued Liabilities (Tables)	9 Months Ended
	Sep. 30, 2024
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	September 30, December 31, ($ in thousands) 2024 2023 Development cost liability $ 105 $ 114 Accrued interest on milestone liabilities 237 101 Accrued audit and legal 652 425 Payroll accruals 233 398 Accrued contracted services and other 95 271 Total accrued expenses $ 1,322 $ 1,309

Note 7 - Preferred Stock (Table

Note 7 - Preferred Stock (Tables)	9 Months Ended
	Sep. 30, 2024
Notes Tables
Fair Value Measurements Of Preferred Stock Valuation Technique [Table Text Block]	January 14 – March 14, April 5 – May 2, 2024 2024 Initial exercise price 20.000 -8.1010 7.000 -1.1515 Stock price on valuation date 8.955 -7.1010 4.522 -1.2323 Risk-free rate 5.10% - 4.82% 5.47% - 5.49% Term (in years) 0.25 - 0.08 0.08 - 0.01 Rounded annual volatility 145% - 130% 110%
Schedule of Stock by Class [Table Text Block]	Consolidated Statement of Operations & Comprehensive Consolidated Balance Sheets Loss Fair value Series A Convertible adjustment to Series A Redeemable Additional derivative Warrant Preferred Preferred paid-in and warrant ($ in thousands) liability Stock Stock capital liabilities Balances, December 31, 2023 $ 3,083 $ 1,742 — $ (7,208 ) $ — Conversion of 202 — (269 ) — 269 — Extinguishment of Series A Preferred Stock — (191 ) — 191 — Deemed dividend on January 14, 2024, modification — 228 — (228 ) — Fair value adjustment (419 ) — — — 419 Balances, March 31, 2024 2,664 1,510 — (6,976 ) 419 Conversion of 1,215 — (1,550 ) — 1,550 — Extinguishment of Series A Preferred Stock — (31 ) — 31 — Deemed dividend on modification of Series A Preferred Stock — 71 — (71 ) — Cashless exercise of 3i Exchange Warrants (405 ) — — 405 — Fair value adjustment (2,243 ) — — — 2,243 Balances, June 30, 2024 $ 16 $ — $ — $ (5,061 ) $ 2,662 Fair value adjustment (14 ) — — — 14 Issuance of redeemable preferred stock — — 2,938 — — Redemption of redeemable preferred stock — — (3,500 ) — — Deemed dividend on redeemable preferred stock — — 562 (562 ) — Balances, September 30, 2024 $ 2 $ — $ — $ (5,623 ) $ 2,676 Consolidated Statement of Operations & Comprehensive Consolidated Balance Sheets Loss Series A Preferred Fair value Convertible adjustment to Stock – Series A Additional derivative Warrant Mezzanine Preferred paid-in and warrant ($ in thousands) liability Equity Stock capital liabilities Balances, December 31, 2022 $ 374 $ 2,001 $ — $ (3,756 ) $ — Conversion of 3,838 — (565 ) — 575 — Fair value adjustment (309 ) — — — 309 Balances, March 31, 2023 65 1,436 — (3,181 ) 309 Conversion of 8,214 — (812 ) (2,522 ) 3,334 — Elimination of redemption rights on Series A Preferred stock; deemed dividend of $ 3,328 — (624 ) 3,952 (3,328 ) — Redemption of 1,550 — — (1,445 ) — — Issuance of 486 350 103 — — 453 — — Exchange of 50,000 5,577 3,959 — — 5,199 (3,959 ) — Fair value adjustment 1,078 — — — (1,078 ) Balances, June 30, 2023 $ 1,143 $ — $ 5,637 $ (7,134 ) $ (769 ) July 10, 2023 modification — — 206 (206 ) — Redemption of 4,630 — — (4,474 ) (526 ) — September 14, 2023 modification — — 373 (373 ) — Fair value adjustment 2,803 — — — (2,803 ) Balances, September 30, 2023 $ 3,946 $ — $ 1,742 $ (8,239 ) $ (3,572 )

Note 8 - Derivative Liabiliti_2

Note 8 - Derivative Liabilities (Tables)	9 Months Ended
	Sep. 30, 2024
Notes Tables
Schedule of Derivative Liabilities at Fair Value [Table Text Block]	Common Share Purchase 3i Exchange ($ in thousands) Warrants Warrants Balance as of January 1, 2023 $ — $ 374 Issuance date fair value of April, July & September 2023 Common share purchase warrants 15,161 — Modifications to fair value upon exercise 592 — Change in fair value adjustment of derivative and warrant liabilities (11,911 ) 1,477 Amount transferred to Equity (1,579 ) (1,031 ) Balance as of December 31, 2023 $ 2,263 $ 820 Fair value per Common warrant / 3i Warrant / issuable at December 31, 2023 $ 264.60 $ 114.00 Common Share Purchase 3i Exchange ($ in thousands) Warrants Warrants Balance at January 1, 2024 $ 2,263 $ 820 Change in fair value adjustment of derivative and warrant liabilities (2,261 ) (415 ) Cashless conversion of 3i Exchange Warrants — (405 ) Balance at September 30, 2024 $ 2 $ — Fair value per Common warrant issuable at September 30, 2024 $ 0.28 $ —
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]	September 2023 April 2023 July 2023 Inducement Warrants Warrants Warrants Initial exercise price $ 600.00 $ 600.00 $ 600.00 Stock price on valuation date $ 2.11 $ 2.11 $ 2.11 Risk-free rate 3.58 % 3.58 % 3.58 % Term (in years) 3.77 3.77 4.45 Rounded annual volatility 124 % 124 % 124 % September 30, 2023 Initial exercise price $ 600.00 Stock price on valuation date $ 450.00 Risk-free rate 5.22 % Expected life of the Warrant to convert (years) 1.22 Rounded annual volatility 152 % Timing of liquidity event Q4 - 2023 Expected probability of event 10 %

Note 9 - Stockholders' Equity (

Note 9 - Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2024
Notes Tables
Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]	Weighted Number of Average Grant Units Date Fair Value Unvested balance at December 31, 2023 — — Granted 174,038 $ 2.36 Unvested balance at September 30, 2024 174,038 $ 2.36
Share-Based Payment Arrangement, Option, Activity [Table Text Block]	Weighted Average Weighted Remaining Aggregate Number Average Contractual Intrinsic Value of Options Exercise Price Term (years) (in thousands) Outstanding at December 31, 2023 9 $ 4,725,600 3.2 — Cancelled/forfeited (2 ) 2,606,960 — — Outstanding at September 30, 2024 7 $ 4,699,177 2.7 — Expected to vest 1 $ 924,000 3.0 — Exercisable 6 $ 5,328,373 2.6 —
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Three Months Ended Nine Months Ended September 30, September 30, ($ in thousands) 2024 2023 2024 2023 Research and development $ 11 $ 121 $ 8 $ 39 General and administrative 6 59 (1 ) 20 Total stock-based compensation expense $ 17 $ 180 $ 7 $ 59

Note 12 - Loss Per Share of C_2

Note 12 - Loss Per Share of Common Stock (Tables)	9 Months Ended
	Sep. 30, 2024
Notes Tables
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	As of September 30, 2024 2023 Warrants 8,557 27,369 Options 7 9 Unvested restricted stock units 174,038 — Series A Convertible Preferred stock — 2,551 182,602 29,929

Note 13 - Financial Instrumen_2

Note 13 - Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2024
Notes Tables
Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]	Fair Value Measurements as of September 30, 2024 ($ in thousands) Level 1 Level 2 Level 3 Total Liabilities: Warrant liability $ — $ — $ (2 ) $ (2 ) $ — $ — $ (2 ) $ (2 ) Fair Value Measurements as of December 31, 2023 ($ in thousands) Level 1 Level 2 Level 3 Total Liabilities: Warrant liability $ — $ — $ (2,263 ) $ (2,263 ) Derivative warrant liability — — (820 ) (820 ) $ — $ — $ (3,083 ) $ (3,083 )

Note 1 - Organization, Princi_2

Note 1 - Organization, Principal Activities and Basis of Presentation (Details Textual) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Retained Earnings (Accumulated Deficit)	$ (111,513)	$ (94,451)
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents	$ 18,500

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies (Details Textual) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
OCI, Foreign Currency Transaction and Translation Gain (Loss), Arising During Period, Tax	$ (0.2)	$ (0.1)	$ (0.3)	$ (37,000)

Note 3 - Intangible Assets (Det

Note 3 - Intangible Assets (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Indefinite-Lived Intangible Assets (Excluding Goodwill)	$ 0	$ 9,800
Asset Impairment Charges	9,700
Foreign Currency Transaction Loss, before Tax	$ 100

Note 4 - Accrued Liabilities -

Note 4 - Accrued Liabilities - Schedule of Accrued Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Development cost liability	$ 105	$ 114
Accrued interest on milestone liabilities	237	101
Accrued audit and legal	652	425
Payroll accruals	233	398
Accrued contracted services and other	95	271
Total accrued expenses	$ 1,322	$ 1,309

Note 5 - Convertible Promisso_2

Note 5 - Convertible Promissory Note Due to Novartis (Details Textual) - USD ($) $ in Thousands	Sep. 30, 2024	Jan. 26, 2024	Dec. 31, 2023
Accounts Payable, Current	$ 4,693		$ 8,416
Convertible Notes Payable, Current	1,337		1,300
Accrued Liabilities, Current	1,322		$ 1,309
Convertible Promissory Note Due to Novartis [Member]
Debt Instrument, Interest Rate, Stated Percentage		5%
Accounts Payable, Current	3,600
Convertible Notes Payable, Current	1,300
Accrued Liabilities, Current	$ 200

Note 6 - Convertible Senior P_2

Note 6 - Convertible Senior Promissory Notes Due to 3i, Lp (3i") (Details Textual) - USD ($)			6 Months Ended
	Mar. 14, 2024	Nov. 22, 2022	Jun. 30, 2023	Feb. 13, 2024	Jan. 18, 2024	Dec. 30, 2022	Nov. 28, 2022
The 2024 3i Convertible Senior Promissory Notes [Member]
Debt Instrument, Interest Rate, Stated Percentage	8%
Debt Instrument, Redemption Price, Percentage	105%
Debt Instrument, Redemption Price, Percentage of Capital Proceeds	20%
The 2023 3i Convertible Secured Promissory Notes [Member]
Debt Instrument, Interest Rate, Stated Percentage		5%
Debt Instrument, Redemption Price, Percentage of Capital Proceeds		35%
Debt instrument, Covenant, Redemption Financing Proceeds Threshold		$ 5,000,000
Debt Instrument, Unamortized Discount		34,000
Interest Expense, Debt			$ 43,000
Interest Expense, Debt, Excluding Amortization			33,000
Amortization of Debt Discount (Premium)			$ 10,000
First Note [Member] | The 2024 3i Convertible Senior Promissory Notes [Member]
Debt Instrument, Face Amount					$ 440,000
Debt Instrument, Convertible, Conversion Price (in dollars per share)					$ 268.5
Debt Instruments Aggregate Purchase Price					$ 400,000
Debt Instrument, Discount Percent					10%
First Note [Member] | The 2023 3i Convertible Secured Promissory Notes [Member]
Debt Instrument, Face Amount		$ 1,700,000
Second Note [Member] | The 2024 3i Convertible Senior Promissory Notes [Member]
Debt Instrument, Face Amount				$ 4,400,000
Debt Instrument, Convertible, Conversion Price (in dollars per share)				$ 243
Debt Instruments Aggregate Purchase Price				$ 400,000
Debt Instrument, Discount Percent				10%
Second Note [Member] | The 2023 3i Convertible Secured Promissory Notes [Member]
Debt Instrument, Face Amount							$ 400,000
Third Note [Member] | The 2024 3i Convertible Senior Promissory Notes [Member]
Debt Instrument, Face Amount	$ 660,000
Debt Instrument, Convertible, Conversion Price (in dollars per share)	$ 210
Debt Instruments Aggregate Purchase Price	$ 600,000
Debt Instrument, Discount Percent	10%
The 2024 3i Convertible Senior Promissory Notes [Member] | First Note [Member]
Debt Instrument, Face Amount						$ 700,000

Note 7 - Preferred Stock (Detai

Note 7 - Preferred Stock (Details Textual) - USD ($)							3 Months Ended						6 Months Ended	9 Months Ended
	Aug. 19, 2024	Mar. 14, 2024	Feb. 14, 2024	Jan. 14, 2024	Apr. 21, 2023	Feb. 28, 2023	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2024	Sep. 30, 2024	Sep. 30, 2023	May 01, 2024	Feb. 13, 2024	Jan. 18, 2024	Dec. 31, 2023
Preferred Stock, Par or Stated Value Per Share (in dollars per share)							$ 0.0001							$ 0.0001					$ 0.0001
Preferred Stock, Shares Outstanding (in shares)							0							0					1,417
Share Price (in dollars per share)																$ 34.5
Preferred Stock, Shares Issued (in shares)							0							0					1,417
Preferred Stock, Value, Issued							$ 0							$ 0					$ 1,742,000
Conversion of Series A Preferred Stock To Common Stock [Member]
Conversion of Stock, Shares Converted (in shares)													1,417	1,417	12,052
Conversion of Stock, Shares Issued (in shares)													15,976	15,976	404
Conversion of Stock, Amount Issued													$ 1,800,000	$ 1,800,000	$ 3,900,000
Conversion of Series C into Series A Preferred Stock [Member]
Conversion of Stock, Shares Converted (in shares)					50,000
Conversion of Stock, Shares Issued (in shares)					5,577
Conversion of Stock, Amount Issued					$ 1,700,000
Conversion of Stock, Amount Converted					5,200,000
Deemed Dividend					1,200,000
Adjustments to Additional Paid in Capital, Increase in Carrying Amount of Redeemable Preferred Stock					$ 4,000,000
Exchange Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 210	$ 243	$ 268.5													$ 234	$ 268.5	$ 600
Class of Warrant or Right, Outstanding (in shares)		27,648		16,411			0							0			18,137	16,411	7,346
Conversion of Warrants or Rights, Warrants or Right Converted (in shares)														121,079
Stock Issued During Period, Shares, Conversion of Warrants (in shares)														78,655
Stock Issued During Period, Value, Conversion of Warrants														$ 400,000
Class of Warrant or Right, Issued (in shares)							0							0
Series A Convertible Preferred Stock [Member]
Dividends, Preferred Stock, Stock														$ 600,000
Redeemable Preferred Stock Dividends							$ 562,000			$ 0				562,000	0
Proceeds from Issuance of Preferred Stock and Preference Stock														2,938,000	0
Conversion of Stock, Amount Converted														$ 1,819,000	3,899,000
Series A Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share (in dollars per share)		$ 1,100,000	1,100,000	$ 1,100,000
Preferred Stock, Convertible, Conversion Price (in dollars per share)		$ 210	$ 243	$ 268.5													$ 243		$ 600
Dividends, Preferred Stock, Stock				$ 228,000
Preferred Stock, Shares Outstanding (in shares)		1,215	1,296	1,417			0	0					0	0					1,417
Fair Value of Preferred Stock				$ 2,000,000
Preferred Stock, Value, Outstanding				$ 1,700,000
Preferred Stock, Convertible, Shares Issuable (in shares)		17,843	16,453	5,699
Gain Loss On Extinguishment Of Preferred Stock		$ 69,000	$ 122,000											$ 200,000
Redeemable Preferred Stock Dividends							$ 0			$ 1,105,000				$ 299,000	$ 8,392,000
Conversion of Stock, Shares Converted (in shares)								1,215	202		8,214	3,838
Preferred Stock, Shares Issued (in shares)							0	0		1,417			0	0	1,417
Stock Repurchased During Period, Shares (in shares)															4,630
Payments for Redemption of Preferred Stock															$ 5,000,000
Series A Preferred Stock [Member] | Conversion of Series C into Series A Preferred Stock [Member]
Conversion of Stock, Shares Converted (in shares)											50,000
Conversion of Stock, Shares Issued (in shares)											5,577
Series C Convertible Preferred Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)						50,000
Shares Issued, Price Per Share (in dollars per share)						$ 24
Proceeds from Issuance of Preferred Stock and Preference Stock						$ 1,200,000								$ 0	$ 1,160,000
Payments of Stock Issuance Costs						40,000
Preferred Stock, Value, Issued						$ 1,500,000
August 2024 SPA [Member] | Series A Convertible Preferred Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)	35,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share)	$ 0.0001
Proceeds from Issuance of Private Placement	$ 2,900,000
Payments of Financing Costs	$ 200,000
Shares Issued, Price Per Share (in dollars per share)	$ 90
Preferred Stock, Convertible, Conversion Price (in dollars per share)	$ 5.1

Note 7 - Preferred Stock - Sche

Note 7 - Preferred Stock - Schedule of Valuation Inputs (Details)	May 02, 2024	Mar. 14, 2024
Measurement Input, Exercise Price [Member] | Maximum [Member]
Preferred stock measurement input	7	20
Measurement Input, Exercise Price [Member] | Minimum [Member]
Preferred stock measurement input	1.15	8.1
Measurement Input, Share Price [Member] | Maximum [Member]
Preferred stock measurement input	4.52	8.95
Measurement Input, Share Price [Member] | Minimum [Member]
Preferred stock measurement input	1.23	7.1
Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]
Preferred stock measurement input	0.0547	0.051
Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]
Preferred stock measurement input	0.0549	0.0482
Measurement Input, Expected Term [Member] | Maximum [Member]
Preferred stock measurement input	0.08	0.25
Measurement Input, Expected Term [Member] | Minimum [Member]
Preferred stock measurement input	0.01	0.08
Measurement Input, Price Volatility [Member]
Preferred stock measurement input	1.10
Measurement Input, Price Volatility [Member] | Maximum [Member]
Preferred stock measurement input		1.45
Measurement Input, Price Volatility [Member] | Minimum [Member]
Preferred stock measurement input		1.30

Note 7 - Preferred Stock - Sc_2

Note 7 - Preferred Stock - Schedule of Stock By Class (Details) - USD ($)				3 Months Ended						9 Months Ended
	Mar. 14, 2024	Feb. 14, 2024	Apr. 21, 2023	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024
Issuance of redeemable preferred stock				$ 5,427,000	$ 27,652,000	$ 40,000
Redemption of Series B Preferred Stock				(3,500,000)			$ (5,000,000)
Conversion of Series C into Series A Preferred Stock [Member]
Conversion of 202 Series A Preferred Stock, net			$ (5,200,000)
Deemed Dividend			$ 1,200,000
Issuance of 486 Series A Preferred stock as repayment of $350 debt; $103 charged to interest expense								$ 1,447,000
Conversion of Debt into Series A Preferred Stock [Member]
Issuance of 486 Series A Preferred stock as repayment of $350 debt; $103 charged to interest expense								453,000
Series A Preferred Stock [Member]
Extinguishment of Series A Preferred Stock	$ 69,000	$ 122,000								$ 200,000
Warrant Derivative Liabilities [Member] | Series A Preferred Stock [Member]
Balance				16,000	2,664,000	3,083,000	1,143,000	65,000		3,083,000
Conversion of 202 Series A Preferred Stock, net					0	0		0	$ 0
Extinguishment of Series A Preferred Stock					0	0
Deemed dividend on January 14, 2024, modification					0	0
Fair value adjustment				(14,000)	(2,243,000)	(419,000)	2,803,000	1,078,000	(309,000)
Cashless exercise of 3i Exchange Warrants					(405,000)
Redemption of redeemable preferred stock				0
Deemed Dividend				0
Balance				2,000	16,000	2,664,000	3,946,000	1,143,000	65,000	2,000
Elimination of redemption rights on Series A Preferred stock; deemed dividend of $3,328								0
Redemption of Series B Preferred Stock							0	0
Warrant Derivative Liabilities [Member] | Series A Preferred Stock [Member] | July 10, 2023 Modification [Member]
Stock modification							0
Warrant Derivative Liabilities [Member] | Series A Preferred Stock [Member] | September 14, 2023 Modification [Member]
Stock modification							0
Warrant Derivative Liabilities [Member] | Series A Preferred Stock [Member] | Conversion of Series C into Series A Preferred Stock [Member]
Issuance of 486 Series A Preferred stock as repayment of $350 debt; $103 charged to interest expense								0
Preferred Stock [Member]
Issuance of redeemable preferred stock				0	3,000
Preferred Stock [Member] | Series A Preferred Stock [Member]
Balance				0	1,510,000	1,742,000	5,637,000	0		1,742,000
Conversion of 202 Series A Preferred Stock, net					(1,550,000)	(269,000)		(2,522,000)	0
Extinguishment of Series A Preferred Stock					(31,000)	(191,000)
Deemed dividend on January 14, 2024, modification					71,000	228,000
Fair value adjustment				0	0	0	0	0	0
Cashless exercise of 3i Exchange Warrants					0
Issuance of redeemable preferred stock				2,938,000
Redemption of redeemable preferred stock				0
Deemed Dividend				0
Balance				0	0	1,510,000	1,742,000	5,637,000	0	0
Elimination of redemption rights on Series A Preferred stock; deemed dividend of $3,328								3,952,000
Redemption of Series B Preferred Stock				(3,500,000)			(4,474,000)	(1,445,000)
Preferred Stock [Member] | Series A Preferred Stock [Member] | July 10, 2023 Modification [Member]
Stock modification							206,000
Preferred Stock [Member] | Series A Preferred Stock [Member] | September 14, 2023 Modification [Member]
Stock modification							373,000
Preferred Stock [Member] | Series A Preferred Stock [Member] | Conversion of Series C into Series A Preferred Stock [Member]
Issuance of 486 Series A Preferred stock as repayment of $350 debt; $103 charged to interest expense								5,199,000
Preferred Stock [Member] | Series A Preferred Stock [Member] | Conversion of Debt into Series A Preferred Stock [Member]
Issuance of 486 Series A Preferred stock as repayment of $350 debt; $103 charged to interest expense								453,000
Common Stock [Member]
Redemption of Series B Preferred Stock							0
Common Stock [Member] | Conversion of Series C into Series A Preferred Stock [Member]
Issuance of 486 Series A Preferred stock as repayment of $350 debt; $103 charged to interest expense								0
Common Stock [Member] | Conversion of Debt into Series A Preferred Stock [Member]
Issuance of 486 Series A Preferred stock as repayment of $350 debt; $103 charged to interest expense								0
Common Stock [Member] | Series A Preferred Stock [Member]
Balance				0	0	0				0
Conversion of 202 Series A Preferred Stock, net					0	0
Extinguishment of Series A Preferred Stock					0	0
Deemed dividend on January 14, 2024, modification					0	0
Fair value adjustment				0	0	0
Cashless exercise of 3i Exchange Warrants					0
Issuance of redeemable preferred stock				2,938,000
Redemption of redeemable preferred stock				(3,500,000)
Deemed Dividend				562,000
Balance				0	0	0				0
Additional Paid-in Capital [Member]
Issuance of redeemable preferred stock				5,427,000	27,649,000	40,000
Redemption of Series B Preferred Stock				0			(526,000)
Additional Paid-in Capital [Member] | Conversion of Series C into Series A Preferred Stock [Member]
Issuance of 486 Series A Preferred stock as repayment of $350 debt; $103 charged to interest expense								(3,752,000)
Additional Paid-in Capital [Member] | Conversion of Debt into Series A Preferred Stock [Member]
Issuance of 486 Series A Preferred stock as repayment of $350 debt; $103 charged to interest expense								0
Additional Paid-in Capital [Member] | Series A Preferred Stock [Member]
Balance				(5,061,000)	(6,976,000)	(7,208,000)	(7,134,000)	(3,181,000)		(7,208,000)
Conversion of 202 Series A Preferred Stock, net					1,550,000	269,000		3,334,000	575,000
Extinguishment of Series A Preferred Stock					31,000	191,000
Deemed dividend on January 14, 2024, modification					(71,000)	(228,000)
Fair value adjustment				0			0
Cashless exercise of 3i Exchange Warrants					405,000
Redemption of redeemable preferred stock				0
Deemed Dividend				(562,000)
Balance				(5,623,000)	(5,061,000)	(6,976,000)	(8,239,000)	(7,134,000)	(3,181,000)	(5,623,000)
Elimination of redemption rights on Series A Preferred stock; deemed dividend of $3,328								(3,328,000)
Redemption of Series B Preferred Stock							(526,000)
Additional Paid-in Capital [Member] | Series A Preferred Stock [Member] | July 10, 2023 Modification [Member]
Stock modification							(206,000)
Additional Paid-in Capital [Member] | Series A Preferred Stock [Member] | September 14, 2023 Modification [Member]
Stock modification							(373,000)
Additional Paid-in Capital [Member] | Series A Preferred Stock [Member] | Conversion of Series C into Series A Preferred Stock [Member]
Issuance of 486 Series A Preferred stock as repayment of $350 debt; $103 charged to interest expense								(3,959,000)
Accumulated Gain (Loss), Financial Liability, Fair Value Option, Attributable to Parent [Member] | Series A Preferred Stock [Member]
Balance				2,662,000	419,000	0	(769,000)	309,000		0
Conversion of 202 Series A Preferred Stock, net					0	0		0	0
Extinguishment of Series A Preferred Stock					0	0
Deemed dividend on January 14, 2024, modification					0	0
Fair value adjustment				14,000		419,000	(2,803,000)	(1,078,000)	309,000
Cashless exercise of 3i Exchange Warrants					0
Redemption of redeemable preferred stock				0
Deemed Dividend				0
Balance				$ 2,676,000	2,662,000	$ 419,000	(3,572,000)	(769,000)	309,000	$ 2,676,000
Elimination of redemption rights on Series A Preferred stock; deemed dividend of $3,328								0
Redemption of Series B Preferred Stock							0	0
Accumulated Gain (Loss), Financial Liability, Fair Value Option, Attributable to Parent [Member] | Series A Preferred Stock [Member] | July 10, 2023 Modification [Member]
Stock modification							0
Accumulated Gain (Loss), Financial Liability, Fair Value Option, Attributable to Parent [Member] | Series A Preferred Stock [Member] | September 14, 2023 Modification [Member]
Stock modification							0
Accumulated Gain (Loss), Financial Liability, Fair Value Option, Attributable to Parent [Member] | Series A Preferred Stock [Member] | Conversion of Series C into Series A Preferred Stock [Member]
Issuance of 486 Series A Preferred stock as repayment of $350 debt; $103 charged to interest expense								0
Series A Convertible Preferred Stock Mezzanine Equity [Member] | Series A Preferred Stock [Member]
Balance							0	1,436,000
Conversion of 202 Series A Preferred Stock, net								(812,000)	(565,000)
Fair value adjustment							0	0	0
Balance							0	0	$ 1,436,000
Elimination of redemption rights on Series A Preferred stock; deemed dividend of $3,328								(624,000)
Redemption of Series B Preferred Stock							0	0
Series A Convertible Preferred Stock Mezzanine Equity [Member] | Series A Preferred Stock [Member] | July 10, 2023 Modification [Member]
Stock modification							0
Series A Convertible Preferred Stock Mezzanine Equity [Member] | Series A Preferred Stock [Member] | September 14, 2023 Modification [Member]
Stock modification							$ 0
Series A Convertible Preferred Stock Mezzanine Equity [Member] | Series A Preferred Stock [Member] | Conversion of Series C into Series A Preferred Stock [Member]
Issuance of 486 Series A Preferred stock as repayment of $350 debt; $103 charged to interest expense								$ 0
Accumulated Gain (Loss), Financial Liability, Fair Value Option, Including Portion Attributable to Noncontrolling Interest [Member] | Series A Preferred Stock [Member]
Fair value adjustment					$ 2,243,000

Note 7 - Preferred Stock - Sc_3

Note 7 - Preferred Stock - Schedule of Stock By Class (Details) (Parentheticals) - USD ($) $ in Thousands		3 Months Ended
	Apr. 21, 2023	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023
Conversion of Series C into Series A Preferred Stock [Member]
Shares converted (in shares)	50,000
Conversion of Stock, Shares Issued (in shares)	5,577
Series A Preferred Stock [Member]
Shares converted (in shares)		1,215	202		8,214	3,838
Deemed dividend					$ 3,328
Redemption shares (in shares)				4,630	1,550
Series A Preferred Stock [Member] | Conversion of Series C into Series A Preferred Stock [Member]
Shares converted (in shares)					50,000
Conversion of Stock, Shares Issued (in shares)					5,577
Deemed Dividend					$ 3,959
Series A Preferred Stock [Member] | Conversion of Debt into Series A Preferred Stock [Member]
Shares issued (in shares)					486
Debt repayment					$ 350
Interest					$ 103

Note 8 - Derivative Liabiliti_3

Note 8 - Derivative Liabilities (Details Textual) - USD ($) $ in Millions	Sep. 30, 2024	Sep. 30, 2023
Derivative Warrant [Member]
Derivative Liability	$ 2	$ 4

Note 8 - Derivative Liabiliti_4

Note 8 - Derivative Liabilities - Schedule of Derivative Liabilities and Fair Value (Details) - Derivative Financial Instruments, Liabilities [Member] - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Common Share Purchase Warrants [Member]
Balance as of January 1, 2023	$ 2,263	$ 0
Issuance date fair value of April, July & September 2023 Common share purchase warrants		15,161
Modifications to fair value upon exercise	0	592
Change in fair value adjustment of derivative and warrant liabilities	(2,261)	(11,911)
Amount transferred to Equity		(1,579)
Balance as of December 31, 2023	$ 2	$ 2,263
Fair value per Common warrant / 3i Warrant / issuable at December 31, 2023 (in dollars per share)	$ 0.28	$ 264.6
Cashless conversion of 3i Exchange Warrants	$ 0	$ (592)
3i Exchange Warrants [Member]
Balance as of January 1, 2023	820	374
Issuance date fair value of April, July & September 2023 Common share purchase warrants		0
Modifications to fair value upon exercise	405	0
Change in fair value adjustment of derivative and warrant liabilities	(415)	1,477
Amount transferred to Equity		(1,031)
Balance as of December 31, 2023	$ 0	$ 820
Fair value per Common warrant / 3i Warrant / issuable at December 31, 2023 (in dollars per share)	$ 0	$ 114
Cashless conversion of 3i Exchange Warrants	$ (405)	$ 0

Note 8 - Derivative Liabiliti_5

Note 8 - Derivative Liabilities - Valuation Techniques (Details)	Sep. 30, 2023	Jul. 31, 2023	Apr. 30, 2023
Measurement Input, Exercise Price [Member] | Espen Garder Haug and Black-Scholes Merton Models [Member] | 3i Exchange Warrants [Member]
Derivative Liability, Measurement Input	600
Expected life of the Warrant to convert (years)Derivative Liability, Measurement Input	600
Measurement Input, Exercise Price [Member] | Black-Scholes-Merton Model [Member] | April 2023 Warrants [Member]
Derivative Liability, Measurement Input			600
Expected life of the Warrant to convert (years)Derivative Liability, Measurement Input			600
Measurement Input, Exercise Price [Member] | Black-Scholes-Merton Model [Member] | July 2023 Warrants [Member]
Derivative Liability, Measurement Input		600
Expected life of the Warrant to convert (years)Derivative Liability, Measurement Input		600
Measurement Input, Exercise Price [Member] | Black-Scholes-Merton Model [Member] | September 2023 Inducement Warrants [Member]
Derivative Liability, Measurement Input	600
Expected life of the Warrant to convert (years)Derivative Liability, Measurement Input	600
Measurement Input, Share Price [Member] | Espen Garder Haug and Black-Scholes Merton Models [Member] | 3i Exchange Warrants [Member]
Derivative Liability, Measurement Input	450
Expected life of the Warrant to convert (years)Derivative Liability, Measurement Input	450
Measurement Input, Share Price [Member] | Black-Scholes-Merton Model [Member] | April 2023 Warrants [Member]
Derivative Liability, Measurement Input			2.11
Expected life of the Warrant to convert (years)Derivative Liability, Measurement Input			2.11
Measurement Input, Share Price [Member] | Black-Scholes-Merton Model [Member] | July 2023 Warrants [Member]
Derivative Liability, Measurement Input		2.11
Expected life of the Warrant to convert (years)Derivative Liability, Measurement Input		2.11
Measurement Input, Share Price [Member] | Black-Scholes-Merton Model [Member] | September 2023 Inducement Warrants [Member]
Derivative Liability, Measurement Input	2.11
Expected life of the Warrant to convert (years)Derivative Liability, Measurement Input	2.11
Measurement Input, Risk Free Interest Rate [Member] | Espen Garder Haug and Black-Scholes Merton Models [Member] | 3i Exchange Warrants [Member]
Derivative Liability, Measurement Input	0.0522
Expected life of the Warrant to convert (years)Derivative Liability, Measurement Input	0.0522
Measurement Input, Risk Free Interest Rate [Member] | Black-Scholes-Merton Model [Member] | April 2023 Warrants [Member]
Derivative Liability, Measurement Input			0.0358
Expected life of the Warrant to convert (years)Derivative Liability, Measurement Input			0.0358
Measurement Input, Risk Free Interest Rate [Member] | Black-Scholes-Merton Model [Member] | July 2023 Warrants [Member]
Derivative Liability, Measurement Input		0.0358
Expected life of the Warrant to convert (years)Derivative Liability, Measurement Input		0.0358
Measurement Input, Risk Free Interest Rate [Member] | Black-Scholes-Merton Model [Member] | September 2023 Inducement Warrants [Member]
Derivative Liability, Measurement Input	0.0358
Expected life of the Warrant to convert (years)Derivative Liability, Measurement Input	0.0358
Measurement Input, Expected Term [Member] | Espen Garder Haug and Black-Scholes Merton Models [Member] | 3i Exchange Warrants [Member]
Derivative Liability, Measurement Input	1.22
Expected life of the Warrant to convert (years)Derivative Liability, Measurement Input	1.22
Measurement Input, Expected Term [Member] | Black-Scholes-Merton Model [Member] | April 2023 Warrants [Member]
Derivative Liability, Measurement Input			3.77
Expected life of the Warrant to convert (years)Derivative Liability, Measurement Input			3.77
Measurement Input, Expected Term [Member] | Black-Scholes-Merton Model [Member] | July 2023 Warrants [Member]
Derivative Liability, Measurement Input		3.77
Expected life of the Warrant to convert (years)Derivative Liability, Measurement Input		3.77
Measurement Input, Expected Term [Member] | Black-Scholes-Merton Model [Member] | September 2023 Inducement Warrants [Member]
Derivative Liability, Measurement Input	4.45
Expected life of the Warrant to convert (years)Derivative Liability, Measurement Input	4.45
Measurement Input, Price Volatility [Member] | Espen Garder Haug and Black-Scholes Merton Models [Member] | 3i Exchange Warrants [Member]
Derivative Liability, Measurement Input	1.52
Expected life of the Warrant to convert (years)Derivative Liability, Measurement Input	1.52
Measurement Input, Price Volatility [Member] | Black-Scholes-Merton Model [Member] | April 2023 Warrants [Member]
Derivative Liability, Measurement Input			1.24
Expected life of the Warrant to convert (years)Derivative Liability, Measurement Input			1.24
Measurement Input, Price Volatility [Member] | Black-Scholes-Merton Model [Member] | July 2023 Warrants [Member]
Derivative Liability, Measurement Input		1.24
Expected life of the Warrant to convert (years)Derivative Liability, Measurement Input		1.24
Measurement Input, Price Volatility [Member] | Black-Scholes-Merton Model [Member] | September 2023 Inducement Warrants [Member]
Derivative Liability, Measurement Input	1.24
Expected life of the Warrant to convert (years)Derivative Liability, Measurement Input	1.24
Expected Probability [Member] | Espen Garder Haug and Black-Scholes Merton Models [Member] | 3i Exchange Warrants [Member]
Derivative Liability, Measurement Input	10
Expected life of the Warrant to convert (years)Derivative Liability, Measurement Input	10

Note 9 - Stockholders' Equity_2

Note 9 - Stockholders' Equity (Details Textual)								3 Months Ended					6 Months Ended	9 Months Ended
	Sep. 30, 2024 USD ($) $ / shares shares	Sep. 12, 2024 shares	Sep. 09, 2024 shares	May 02, 2024 USD ($) $ / shares shares	Apr. 12, 2024 $ / shares shares	Apr. 04, 2024	Mar. 19, 2024 USD ($) $ / shares	Sep. 30, 2024 USD ($) $ / shares shares	Jun. 30, 2024 shares	Mar. 31, 2024 USD ($) $ / shares shares	Jun. 30, 2023 shares	Mar. 31, 2023 shares	Jun. 30, 2024 USD ($) shares	Sep. 30, 2024 USD ($) $ / shares shares	Sep. 30, 2023 USD ($) shares	Sep. 29, 2024 shares	Sep. 08, 2024 shares	Sep. 03, 2024 shares	Mar. 14, 2024 shares	Feb. 14, 2024 shares	Jan. 14, 2024 shares	Dec. 31, 2023 $ / shares shares
Common and Preferred Stock, Shares Authorized (in shares)			250,500,000														750,500,000
Common Stock, Shares Authorized (in shares)	250,000,000		250,000,000					250,000,000						250,000,000			750,000,000					750,000,000
Common Stock, Shares, Outstanding (in shares)	2,759,070							2,759,070		228,487				2,759,070								9,812
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares	$ 0.0001							$ 0.0001		$ 0.0001				$ 0.0001								$ 0.0001
Equity Offering, Amount Available | $	$ 15,900,000							$ 15,900,000						$ 15,900,000
Proceeds from Issuance of Common Stock | $														$ 33,119,000	$ 0
Preferred Stock, Shares Issued (in shares)	0							0						0								1,417
Warrants and Rights Outstanding | $	$ 0							$ 0						$ 0
Stock Issued During Period, Value, Issued for Services | $										$ 90,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)	353,156							353,156						353,156		72,278		353,163
Preferred Stock, Shares Outstanding (in shares)	0							0						0								1,417
Share-Based Compensation Arrangement by Share-Based Payment Award, Annual Percentage Increase	5%							5%						5%
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)														0
Inducement Awards [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)	118,483	55,555
Restricted Stock [Member]
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | $	$ 400,000							$ 400,000						$ 400,000
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)	2 years
Share-Based Payment Arrangement, Option [Member]
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | $	$ 2,000							$ 2,000						$ 2,000
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)	1 year
Former CEO [Member]
Stock Issued During Period, Shares, Issued for Services (in shares)								484
Stock Issued During Period, Value, Issued for Services | $								$ 90,000
Series A Preferred Stock [Member]
Conversion of Stock, Shares Converted (in shares)									1,215	202	8,214	3,838
Preferred Stock, Shares Issued (in shares)	0							0	0				0	0	1,417
Preferred Stock, Shares Outstanding (in shares)	0							0	0				0	0					1,215	1,296	1,417	1,417
Conversion of Series A Preferred Stock To Common Stock [Member]
Conversion of Stock, Shares Converted (in shares)													1,417	1,417	12,052
Conversion of Stock, Shares Issued (in shares)													15,976	15,976	404
Conversion of Stock, Amount Issued | $													$ 1,800,000	$ 1,800,000	$ 3,900,000
Exchange Warrant Conversion To Common Stock [Member]
Conversion of Stock, Shares Issued (in shares)				75,832	2,824
Conversion of Warrants or Rights, Warrants or Right Converted (in shares)				114,413	6,667
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares				$ 34.5	$ 69
Minimum [Member]
Entity Public Float | $				$ 75,000,000
ATM [Member]
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares							$ 100
Stock Issued During Period, Shares, New Issues (in shares)								1,493,878						2,556,927
Proceeds from Issuance of Common Stock | $								$ 5,400,000						$ 33,100,000
Commission Fee, Percentage				3%
ATM [Member] | Maximum [Member]
Proceeds from Issuance of Common Stock | $							$ 50
Post Reverse Stock Split [Member]
Common Stock, Shares, Outstanding (in shares)										11,426
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio			30			20
Stock Issued During Period, Shares, New Issues (in shares)			97,190

Note 9 - Stockholders' Equity -

Note 9 - Stockholders' Equity - Summary of Restricted Stock Unit Activity (Details) - Restricted Stock Units (RSUs) [Member]	3 Months Ended
	Sep. 30, 2024 $ / shares shares	Dec. 31, 2023 $ / shares shares
Unvested balance, units (in shares) | shares	174,038	0
Unvested balance, fair value (in dollars per share) | $ / shares	$ 2.36	$ 0
Grants, units (in shares) | shares	174,038
Grants, fair value (in dollars per share) | $ / shares	$ 2.36
Unvested balance, units (in shares) | shares	174,038
Unvested balance, fair value (in dollars per share) | $ / shares	$ 2.36

Note 9 - Stockholders' Equity_3

Note 9 - Stockholders' Equity - Summary of Stock Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Outstanding at December 31, 2023 (in shares)	9
Outstanding at December 31, 2023 (in dollars per share)	$ 4,725,600
Outstanding at December 31, 2023 (Year)		3 years 2 months 12 days
Outstanding at December 31, 2023		$ 0
Cancelled/forfeited, Shares (in shares)	(2)
Cancelled or expired, weighted average exercise price (in dollars per share)	$ 2,606,960
Cancelled/forfeited, intrinsic value (in dollars per share)	$ 0
Outstanding at September 30, 2024 (in shares)	7
Expected to vest, shares (in shares)	1
Expected to vest, weighted average exercise price (in dollars per share)	$ 924,000
Expected to vest, remaining average life (Year)	3 years
Expected to vest, intrinsic value	$ 0
Exercisable, shares (in shares)	6
Exercisable, weighted average exercise price (in dollars per share)	$ 5,328,373
Exercisable, remaining average life (Year)	2 years 7 months 6 days
Exercisable, intrinsic value	$ 0

Note 9 - Stockholders' Equity_4

Note 9 - Stockholders' Equity - Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Stock-based compensation expense	$ 17	$ 180	$ 7	$ 59
Research and Development Expense [Member]
Stock-based compensation expense	11	121	8	39
General and Administrative Expense [Member]
Stock-based compensation expense	$ 6	$ 59	$ (1)	$ 20

Note 10 - License and Develop_2

Note 10 - License and Development Agreements (Details Textual) - USD ($)	6 Months Ended
	Jun. 30, 2024	Sep. 30, 2024	Sep. 01, 2024	May 01, 2024	Mar. 01, 2024	Jan. 26, 2024	Dec. 31, 2023	May 26, 2023
Accounts Payable, Current		$ 4,693,000					$ 8,416,000
Convertible Notes Payable, Current		1,337,000					1,300,000
Accrued Liabilities, Current		1,322,000					$ 1,309,000
Milestone Payment, Sales	$ 50,000,000
Licensed Product Sales	1,000,000,000
Maximum [Member]
Milestone Payment	$ 94,000,000
Already Paid [Member]
License Agreement, Periodic Payment								$ 100,000
Paid Within 10 Days of Fourth Amendment Execution [Member]
License Agreement, Periodic Payment								50,000
Completion of Capital Raise [Member]
License Agreement, Periodic Payment								$ 100,000
Payment on or Before March 1, 2024 [Member]
License Agreement, Periodic Payment					$ 850,000
Fifth Amendment Agreement [Member]
License Agreement, Periodic Payment				$ 200,000
Payment Due by September 1, 2024 [Member]
License Agreement, Periodic Payment			$ 850,000
Convertible Promissory Note Due to Novartis [Member]
Debt Instrument, Interest Rate, Stated Percentage						5%
Accounts Payable, Current		3,600,000
Convertible Notes Payable, Current		1,300,000
Accrued Liabilities, Current		$ 200,000
Eisai Royalties One [Member] | Maximum [Member]
Royalty Annul Percentage	10%
Payments for Royalties	$ 100,000,000
Eisai Royalties One [Member] | Minimum [Member]
Royalty Annul Percentage	5%
Payments for Royalties	$ 0
Eisai Royalty Two [Member] | Maximum [Member]
Royalty Annul Percentage	10%
Payments for Royalties	$ 250,000,000
Eisai Royalty Two [Member] | Minimum [Member]
Royalty Annul Percentage	6%
Payments for Royalties	$ 100,000,000
Eisai Royalties Three [Member] | Maximum [Member]
Royalty Annul Percentage	11%
Payments for Royalties	$ 500,000,000
Eisai Royalties Three [Member] | Minimum [Member]
Royalty Annul Percentage	7%
Payments for Royalties	$ 250,000,000
Eisai Royalties Four [Member]
Payments for Royalties	$ 500,000,000
Eisai Royalties Four [Member] | Maximum [Member]
Royalty Annul Percentage	15%
Eisai Royalties Four [Member] | Minimum [Member]
Royalty Annul Percentage	11%

Note 11 - Related Party (Detail

Note 11 - Related Party (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Related Party [Member] | Director [Member]
Payments for Other Fees	$ 0	$ 32,000	$ 200,000	$ 100,000

Note 12 - Loss Per Share of C_3

Note 12 - Loss Per Share of Common Stock - Schedule of Antidilutive Securities (Details) - shares	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Antidilutive Securities (in shares)	182,602	29,929
Warrant [Member]
Antidilutive Securities (in shares)	8,557	27,369
Share-Based Payment Arrangement, Option [Member]
Antidilutive Securities (in shares)	7	9
Unvested Restricted Stock Units [Member]
Antidilutive Securities (in shares)	174,038	0
Series A Convertible Preferred Stock [Member]
Antidilutive Securities (in shares)	0	2,551

Note 13 - Financial Instrumen_3

Note 13 - Financial Instruments - Fair Value Measurements On a Recurring Basis (Details) - Fair Value, Recurring [Member] - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Derivative Liability	$ (2)	$ (3,083)
Fair Value, Inputs, Level 1 [Member]
Derivative Liability	0	0
Fair Value, Inputs, Level 2 [Member]
Derivative Liability	0	0
Fair Value, Inputs, Level 3 [Member]
Derivative Liability	(2)	(3,083)
Warrant [Member]
Derivative Liability	(2)	(2,263)
Warrant [Member] | Fair Value, Inputs, Level 1 [Member]
Derivative Liability	0	0
Warrant [Member] | Fair Value, Inputs, Level 2 [Member]
Derivative Liability	0	0
Warrant [Member] | Fair Value, Inputs, Level 3 [Member]
Derivative Liability	$ (2)	(2,263)
Derivative Warrant [Member]
Derivative Liability		(820)
Derivative Warrant [Member] | Fair Value, Inputs, Level 1 [Member]
Derivative Liability		0
Derivative Warrant [Member] | Fair Value, Inputs, Level 2 [Member]
Derivative Liability		0
Derivative Warrant [Member] | Fair Value, Inputs, Level 3 [Member]
Derivative Liability		$ (820)

Note 15 - Subsequent Events (De

Note 15 - Subsequent Events (Details Textual) - USD ($) $ in Thousands	1 Months Ended	9 Months Ended
	Nov. 13, 2024	Sep. 30, 2024	Sep. 30, 2023
Proceeds from Issuance of Common Stock		$ 33,119	$ 0
Subsequent Event [Member]
Stock Issued During Period, Shares, New Issues (in shares)	1,534,356
Proceeds from Issuance of Common Stock	$ 2,500